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Abstract

DISTINCT T CELL CLONES ARE ASSOCIATED WITH GRAFT-VERSUS-HOST DISEASE
(GVHD), AND POTENTIALLY GRAFT-VERSUS-TUMOR (GVT), RESPONSES FOLLOWING
ALLOGENEIC STEM CELL TRANSPLANTATION
By Jennifer Berrie

A Dissertation submitted in partial fulfillment of the requirements for the degree of Master’s of Science
at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Director: Masoud Manjili, DVM, PhD
Professor of Microbiology and Immunology

In patients undergoing hematopoietic stem cell transplantation (HSCT) with HLA-identical donors,
genetic polymorphisms result in a mismatch between donors and recipients in their minor
histocompatibility antigens (mHAgs), and tumors may also express tumor-associated antigens (TAA)
that may not be abundantly present in the donors. Donor T cells can recognize such mHAgs and TAAs
as foreign antigens and generate an objective response against hematologic malignancies in a graftversus-tumor (GVT) effect. However, a major side effect of HSCT occurs when donor T cells are
alloreactive against the recipients’ normal cells, leading to graft-versus-host disease (GVHD). The
ability to identify T cell clones that are exclusively involved in the GVT or GVHD responses remains
elusive. In this study, we looked at clonally-driven CD3+ T cells in patients with hematologic
malignancies prior to and after transplantation. We identified V families of increased expression

involved in GVHD or GVT responses, with Vs 4, 11, and 23 being associated with GVHD, Vs 9, 16,
and 20 being associated with GVT, and Vs 2, 3, 7, 8, 12, 15, and 17 being involved in GVHD and/or
GVT. We were also able to identify some of the V families that were increased in the peripheral
blood at the site of GVHD. Furthermore, one of our twelve patients had donor lymphocyte infusions
(DLIs) for treatment of relapse, from which we were able to observe oligoclonal T cells that emerged at
the time of post-DLI remission and re-establishment of GVHD.

ix

Introduction

Hematologic cancers
It was estimated that over 1.5 million people were diagnosed with cancer in 2010, and that over
500,000 died from their disease.1 Of these diagnoses, over 43,000 were with leukemia, roughly 74,000
with lymphoma, and about 20,000 with myeloma.1 Leukemia, lymphoma, and myeloma are all blood
cancers that derive from hematopoietic stem cells (HSCs). Leukemias are defined by their cell
precursors—either lymphoid or myeloid. Lymphomas are derived from lymphocytes, and can be further
classified as Hodgkin’s or Non-Hodgkin’s Lymphoma. Myelomas are derived from plasma cells.
Regardless of which cell types these cancers arise from, they are each a result of a dysregulation and
malignant state of the hematopoietic system. The treatment of many blood cancers requires high doses
of chemotherapy and/or radiation treatments that destroy not only cancer cells, but also the patient’s
healthy bone marrow.
Hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) involves intravenous infusion of hematopoietic stem
and progenitor cells to restore normal hematopoiesis and/or treat blood malignancies. The clinical
application of HSCT originated in the clinical observations of severe myelosuppressive effects from
radiation among nuclear bomb survivors at Nagasaki and Hiroshima.2 In the 1950s and 1960s, research
efforts were made to develop means of reversing myelosuppressive effects, including the infusion of
bone marrow. Subsequent determination and understanding of the major histocompatibility complex
(MHC) and human leukocyte antigens (HLA) as the major determinant of graft rejection helped to
1

advance the clinical application of HSCT.2 Since the first successful transplantations in the 1960s and
1970s, HSCT is now a standard treatment, and is performed in patients with various malignant and nonmalignant disorders in order to restore lymphohematopoiesis, replace diseased marrow, and reconstitute
lymphohematopoiesis after marrow-ablative conditioning regimens.2,3
Prior to transplantation, patients undergo preparative regimens that are either myeloablative or nonmyeloablative. The three major purposes of myeloablative conditioning regimens are to: eradicate
malignant disease, suppress the recipient’s immune system (to decrease the chance for graft rejection),
and create space in the bone marrow microenvironment to allow engraftment of the donor stem cells.3
The donor HSCs, also referred to as the graft, may be autologous (from the patient him- or herself),
syngeneic (from an identical twin), or allogeneic (from any person other than the patient or an identical
twin.2
The success of HSCT in treating hematological malignancies is continually limited by acute
complications such as infectious conditions, veno-occlusive disease of the liver, and acute and chronic
graft-versus-host disease (GVHD).3 Due to preparative regimens with chemotherapy and/or radiation
before HSCT, recipients suffer deficiencies in their cellular and humoral aspects of their immune system
for a variable duration.3 The cellular immunodeficiency involves decreased T cell response to
alloantigens and mitogens, decreased helper CD4+ T cell function, and decreased activity to intradermal
skin tests. Due to the thymic involution in recipients, T cell function is dependent upon the peripheral
expansion of the few donor T cells that are present in the graft.3 Humoral immunodeficiency consists of
a decrease in IgG isotype switching and antigen-specific responses, resulting in an impaired production
of antibodies to pathogens.3 Recovery of the immune system occurs within the first six months to year
after HSCT. However, immunodeficiency is prolonged and more profound in patients with GVHD who
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are under immunosuppressive therapy, and recovery of the immune system for these patients occurs
after the discontinuation of their GVHD therapies.3
Graft-versus-host disease
Graft-versus-host disease develops when immunocompetent donor T cells are alloreactive against
recipient tissues and organs.4,5 In 1966, Billingham outlined three general criteria for GVHD: 1) the
donor cells must be immunologically competent; 2) the recipient must be immunocompromised, or
incapable of rejecting the graft; and, 3) the recipient must express tissue antigens that are not present in
the donor, such that they may be recognized as non-self.4-6 The genetic basis for the third criterion, that
GVHD is a result of donor cells recognizing host antigens as non-self, is derived from genetic
polymorphisms of the HLA and non-HLA systems (minor histocompatibility antigens (mHAgs), killer
cell immunoglobulin-like receptors (KIRs), cytokines, and NOD2 genes).7,8 As a result of alloreactive T
cells recognizing these genetic incompatibilities, there is poorer overall survival (OS) in those
individuals who develop GVHD.9
Risk factors for GVHD include: donor-recipient match at MHC loci (mismatches in HLA class I
HLA-A, -B, -C or class II HLA-DRB1), donor stem cell source (bone marrow (BM) or peripheral blood
stem cells (PBSC)), T cell dose, and other factors including donor and recipient age, donor-recipient sex
mismatch (male recipient of female graft), donor parity and allosensitization, disease stage, and intensity
of conditioning.10 General associations have been made with certain allele-level mismatches in the HLA
genes, with mismatching of class I alleles being associated with increased risk of GVHD or graft
rejection, whereas mismatching of the class II alleles has been associated with increased incidence of
GVHD with no impact on graft rejection.9,10
Today, GVHD is broadly categorized as chronic or acute. Historically, GVHD was classified as
chronic if it presented after 100 days post-HSCT, regardless if it was clinically indistinguishable from
3

acute GVHD (aGVHD).11 This classification was not satisfactory because acute and chronic GVHD
have distinct clinical features that may sometimes present concomitantly and/or independent of the
actual duration after transplant. The NIH consensus now includes classification of GVHD as late-onset
aGVHD (after day 100) and an overlap syndrome that has features of both acute and chronic GVHD.8,11
Acute GHVD
Acute GVHD is graded (I-IV) based on the extent and severity of the involvement of the three major
affected organs—the skin, liver, and gastrointestinal (GI) tract.3 Grades II to IV occur in roughly 2050% of patients who receive stem cell grafts from an HLA-matched sibling and in approximately 5080% of patients who receive grafts from an HLA-mismatched sibling or an HLA-matched unrelated
donor (MUD).3 Long-term survival of patients with aGVHD is roughly 50% for those with grades 0-I
and is as low as 11% for those with grade IV.10 Acute GVHD is characterized by dermatitis, hepatitis,
and enteritis. The onset of aGVHD is usually marked by a maculopapular rash involving the face, trunk,
extremities, palms, soles, and ears.10
There is a general three phase model of the development of aGVHD: 1) activation of antigenpresenting cells (APCs); 2) donor T cell activation, proliferation, differentiation, and migration; and 3)
destruction of target tissue.4,5,7,8 The immune response is primed during phase one, in which APCs are
activated by underlying disease and conditioning regimens.7,8,12 Conditioning regimens cause tissue
damage, resulting in the production of ―danger signals,‖ including pro-inflammatory cytokines and
chemokines, microbial products (i.e. – LPS, CpG) that enter systemic circulation from damaged
intestinal mucosa, and necrotic cells.4,5,8,13,14 The inflammatory response promotes the activation and
maturation of APCs, in which there is an increased expression of MHC, adhesion, and costimulatory
molecules on host APCs, leading to an enhanced ability of donor T cells to recognize alloantigens, and
subsequently become activated and proliferate.8,15 Phase two represents the core of the GVHD reaction
4

in which donor T cells are activated in response to host APC. T cell activation is induced when T cell
receptors (TCRs) recognize peptide:MHC complexes on APCs, and further requires a second signal
which is generated by ligation of costimulatory molecules on APCs with their cognate receptors on T
cells.7 These activated alloreactive T cells expand and differentiate into Th1/Tc1 or Th2/Tc2 cells, each
of which has been associated with differences in the manifestation of GVHD,7 though Th1- and Tc1type cytokines (IL-1, IL-6, and TNF-produced by macrophages and monocytes;IFN- and IL-2
produced by CD4 Th1 and CD8 Tc1 cells) are predominantly associated with development of aGVHD.16
Once activated, these T cells migrate to target tissues and subsequently recruit other effector leukocytes.
The homing of these T cells is regulated by adhesion, addressin, and chemokine receptor molecules in
response to the production of chemokines in the injured target tissue, which is initiated by the
conditioning regimen and is later amplified by the disease process.7 The effector, and third phase, is a
complex cascade of both cellular mediators (such as cytotoxic T lymphocytes (CTLs) and natural killer
(NK) cells) and soluble inflammatory mediators (such as TNF-α, IFN-γ, IL-1, and NO) that cause
destruction of target tissue.8,15 With regards to cellular effectors, CTLs that preferentially use the
Fas/FasL pathway of target lysis appear to predominate in GVHD damage of the liver (as hepatocytes
express large amounts of Fas), whereas CTLs that use the perforin/granzyme pathways are more
important in GVHD of the GI tract and skin.8 This effector stage of GVHD is perpetuated by the
increased inflammatory signaling that is caused by tissue damage.7 Inflammatory effectors may be
secreted as a result of stimulation of toll-like receptors (TLRs) by microbial products (such as LPS) that
leak through intestinal mucosa or skin that is damaged from conditioning regimens.4,8 For this reason, it
is thought that Peyer’s patches in the gut are initial sites of donor T cell activation by host APCs.7,8
Chronic GVHD
Chronic GVHD can occur in up to 60% of patients who survive beyond 100 days after allogeneic
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HSCT, and is a complication that develops more frequently 3 to 6 months after engraftment.10,17,18 In
roughly 20% of patients with cGVHD, there is no evidence of previous aGVHD, suggesting that the two
disease types have different pathogenesis. Chronic GVHD is clinically manifested in a manner similar
to that of autoimmune disorders, particularly scleroderma,3 and in contrast to aGVHD, is often
characterized by fibrosis of the affected tissue or organ.8 There are a multitude of manifestations of
cGVHD, including: sicca syndrome (drying of the mouth and eyes), skin lesions (hypo- or
hyperpigmentation, decreased elasticity, and loss of hair follicles and sweat glands), oral mucositis,
esophageal strictures, kerato-conjunctivitis, malabsorption, hepatic involvement with
hyperbilirubinemia, and suppressed hematopoietic reconstitution.3 Ten to twenty percent of patients
with cGVHD develop bronchiolitis obliterans, which is associated with hypogammaglobulinemia and
poor outcome.3
Like aGVHD, cGVHD is also thought to be induced by donor T cells, but the nature of relevant
antigens and T cell subsets, as well as the mechanisms of cGVHD, are less well understood.3,8 There is
an absence of appropriate experimental models that mimic all of the features of cGVHD, and this might
be due to differences between the human and experimental species.8,17 Current animal models for
cGVHD are difficult to relate to patient outcomes since chronic models more closely mimic nonmyeloablative transplants than full ablative allogeneic transplants, thus making the pathophysiology of
cGVHD still poorly defined.17 Another difference is that, in contrast to murine studies, the kinetics of
clinical cGVHD is slower and only observed after prophylaxis and/or treatment for aGVHD. Even if
clinical cGVHD arises de novo and in the absence of active immunosuppression (ISP), it is not possible
to definitively rule out the impact of either GVHD prophylaxis and/or subclinical aGVHD on the
subsequent development of cGVHD.8 Some experimental models have shown that T cells from animals
with cGVHD are specific for a common (shared between donor and host) determinant of MHC class II
6

molecules and are consequently considered ―autoreactive.‖8 Such autoreactive T cells are associated
with a damaged thymus and the inability to delete autoreactive clones.17 It has also been shown that
autoreactive T cells can interact with IFNγ to produce the increased collagen deposition seen in chronic
GVHD of the skin.17 Many experimental models of cGVHD have been characterized by Th2-type
responses involving upregulation of Th2 cytokines (IL-4, IL-5, IL-10, TGF-) and antibody-mediated
damage.7,15-17 The association of antibodies with cGVHD is also supported by the clinical observation
in female to male HSCT in which antibodies specific to Y chromosome-encoded mHAgs are present.8
Aside from the clinical correlation of antibodies with cGVHD, both Th1 and Th2 responses have been
implicated in humans post-HSCT.8,19
Despite experimental evidence and clinical resemblance to autoimmune diseases, there is a lack of
clear clinical data on the isolation of donor-derived T cell clones that recognize non-polymorphic
antigens from both the recipients and donors.8 Instead, emerging clinical data show a strong correlation
between the presence of immune responses against ubiquitously expressed mHAgs and cGVHD.8,20
Acute GVHD is recognized more as a generalized state of donor-derived inflammation, in which tissue
damage is mediated by activated donor effector cells and inflammatory cytokines.16 On the other hand,
cGVHD is more representative of chronic antigen-stimulated specific cellular and humoral immune
responses directed against specific epithelial tissues and hematopoietic cells.8,16
Current prophylaxis of GVHD includes immunosuppressive therapies (i.e.- cyclosporine,
methotrexate) that have led to reductions in the incidences of GVHD, yet these therapies suppress T cell
responses not only involved in GVHD, but also the immune system as a whole.3 Other preventative
methods have attempted to reduce the incidence of GVHD by depleting T cells from the graft (TCD),
but these treatments also led to increased risk of graft rejection, opportunistic infection, and relapse
secondary to decreased graft-versus-tumor (GVT) effect.3,21 Established GVHD is predominantly
7

treated with high-dose corticosteroid treatments (i.e. - methylprednisolone), though this treatment fails
for some patients who then must undergo salvage therapy. Second line treatments include
extracorporeal photophoresis (ECP), anti-thymocyte globulin (ATG), cytokine blockades (i.e. – TNFα
antibodies), anti-CD3 antibodies, and chemotherapeutic agents (i.e. – nucleoside analogs), among
others.3,10,22,23 These current broad spectrum treatments are not ideal because they render patients
susceptible to relapse and infectious complications.
Graft-versus-tumor effect
Beyond restoring lymphohematopoiesis, it was eventually found that donor cells were capable of
providing an immunological response against malignant and diseased recipient cells, independent of
chemotherapy and radiation treatments. In 1956, Barnes et al. demonstrated that irradiated mice that
received allogeneic marrow transplants, but not syngeneic transplants, showed remission of leukemia.24
This murine experiment was the first to suggest that donor cells may provide a graft-versus-leukemia
(GVL) or graft-versus-tumor (GVT) effect. The implications of this murine experiment were realized in
human studies showing that relapse rates in patients were decreased in those who developed some form
of GVHD, suggesting that alloreactive donor cells were involved not only in GVHD but also in a GVT
effect.9 It is because of experimental and clinical validations of the importance of donor alloreactivity
that HSCT is becoming more of an immunotherapy, as opposed to an initial means of delivering high
dose therapies and replacing damaged hematopoietic cells with normal stem cells.9,21
It has also been shown that relapse rates are higher in patients who receive TCD grafts or who
receive grafts from identical twins (syngeneic),25 suggesting the role for T cells in alloreactivity of GVT
responses. The significant role of immunocompetent donor cells has been further shown in patients who
received donor lymphocyte infusions (DLI) post-transplant to treat recurrence of disease.25-27 Many
experimental and human models focus on CTLs and NK cells, with CD8+ T cells being the predominant
8

T cell subset implicated in the GVT effect.28-33 The dominance of one subset over another likely varies
with degree of genetic disparities between donors and recipients, both with regards to HLA and
mHAgs.34 Furthermore, there are three general ideas as to how GVT effects are mediated: 1) through
direct killing of malignant cells by perforin- and granzyme-mediated attack from CTLs (CD8+ and CD4+
T cells, and NK cells); 2) by apoptotic cell death via the Fas/FasL pathway (CD8+ and CD4+ T cells); or
3) by cytokine-mediated malignant cell death (CTLs) or control of proliferation (predominantly CD4+ T
cells) [reviewed in Barrett, 1997].34 Aside from helper roles in augmenting CD8+ CTL responses, CD4+
T cells have also been associated with cytotoxic function in a class II-restricted fashion.29,34-37
Just as in GVHD, mHAgs are key players in the GVT effect in HLA-matched allogeneic HSCT.
There has been an association of cGVHD with lower relapse rates, but it isn’t known if the GVT effect
relies on cGVHD or if it independently persists once cGVHD is resolved.17, 25 There are two general
types of antigens that may be targeted in a GVT capacity – polymorphic mHAgs or autologous antigens
that are specifically associated with a malignant phenotype (tumor-associated antigens, or, TAAs).9,28,38
Minor histocompatibility antigens
Minor histocompatibility antigens are peptide epitopes that are derived from the degradation of
normal cellular proteins, and are presented on either MHC class I or class II molecules.15 mHAgs are a
result of genetic variation, though the means of this variation is diverse. Genomic variations may occur
via gene deletions, inverted gene sequences, multiple copy gene duplications, segmental duplications,
large-scale copy number variations (CNVs) and single nucleotide polymorphisms (SNPs).15
Nonsynonymous coding SNPs and deletion polymorphisms are crucial players in the generation of
potentially immunogenic transplantation antigens as they have been identified most in autosomal
mHAgs, and SNPs cause differences in the amino acid sequences of homologous proteins between
recipient and donors cells. A single amino acid substitution can cause altered proteosomal cleavage,
9

peptide transport, HLA binding or TCR contact, all of which may trigger donor T cells to recognize
these peptides as non-self.15
Some of the most common mHAgs studied with regards to HSCT are from genes on the Y
chromosome, which have shown polymorphisms with the homologous regions of the X chromosome. In
the HSCT setting, this is relevant in sex-mismatched transplants in which male patients are recipients of
female stem cell grafts. It has been shown that male recipients of female grafts have a higher risk of
developing GVHD and a lower risk of relapse, suggesting that some mHAgs encoded on the Y
chromosome may be immunodominant.15,29,39 HA-Y mHAgs are ubiquitously expressed,40,41 and some
of the mHAgs encoded on the Y chromosome include UTY, SMCY, and DBY.42 SMCY and DBY are
highly expressed on epithelial cells, suggesting a role for T-cell-mediated responses against these
mHAgs in either GVHD or GVT effects.42 UTY is only moderately expressed on epithelial cells,
suggesting that UTY-specific T cells may promote GVT effects without augmenting GVHD.42
Other mHAgs that are commonly studied are HA-1, -2, and -3. HA-1 and HA-2 are preferentially
expressed on hematopoietic tissues, therefore allowing them to be targeted by HA-1 and HA-2-specific
T cells in a GVT effect without augmenting GVHD (though HA-1 expression has also been implicated
in solid tumors).16,20,32,38 HA-3 is preferentially expressed on non-hematopoietic tissues, suggesting it
may be a target of GVHD more so than GVT effects.42 Overall with regards to mHAgs, those that are
ubiquitously expressed are prime targets for GVHD, whereas those that are restricted to the
hematopoietic system may fulfill their role in eliciting a GVT response without increasing the risks of
GVHD.16,32,43

However, it has also been shown that hematopoietic cells at the site of GVHD may have

a role in the development of low grade GVHD, even though the mHAgs themselves are not ubiquitously
expressed on the actual tissues involved in GVHD.20
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The HLA System
The immunological reactions that are involved in the transplantation process—GVHD and GVT
effects—develop primarily from the HLA system, which is essential in T cell activation through the
HLA presentation of peptides to T cells.9 The HLA genes are located within the MHC on the short arm
of chromosome 6, and includes over 200 genes.44 The HLA class I genes code for the α polypeptide
chain of the class I molecule, whereas the β chain is encoded by the β2-microglobulin gene on
chromosome 15. There are five domains in the α chain: two peptide-binding (α1 and α2), one
immunoglobulin-like (α3), a transmembrane region, and a cytoplasmic tail. Of 20 HLA class I genes,
three are the major components of the immune system: HLA –A, –B, and –C.44 Unlike class I, the class
II genes for both the α and β polypeptide chains are located on chromosome 6. The class II genes are
designated by three letters: the first represents the class (D), the second represents the family (M, O, P,
Q, or R), and the third represents the chain (A or B, which corresponds to α or β, respectively). There
are four domains in each of the α and β chains: peptide-binding (α1 or β1), immunoglobulin-like (α2 or
β2), the transmembrane region, and the cytoplasmic tail.44 These two classes contain the major
influential genes that are matched between donor and recipient in HSCT—HLA-A, -B, and –C genes
from class I, and HLA-DRB1, -DQB1, and –DPB1 genes from class II.9
Class I genes are expressed on most all nucleated cells, though their level of expression is tissuedependent.9,44 Class II gene expression is restricted to hematopoietic cells, and are expressed
predominantly on immune cells (APCs—including B cells, dendritic cells, and macrophages; and also
thymic epithelial cells).25,44 Furthermore, the expression of class II HLA molecules can be induced
during inflammatory responses, such as in the presence of IFN-γ.9,44 Class I molecules are recognized
by CD8+ T cells, and class II molecules are recognized by CD4+ T cells.8,9
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Class I and class II molecules present peptides to the TCR, and hence are involved in the activation
of T cells associated with both GVHD and GVT effects. Traditionally, class I molecules present
endogenous proteins, whereas class II molecules present exogenous proteins, though these designations
are not absolute.45 Class I molecules may present exogenous proteins, such as bacterial proteins, and
class II molecules may present endogenously produced proteins such as viral proteins, though the
mechanisms of these exceptions to the general rule are not well understood.44
Endogenous proteins are primarily marked by ubiquitin for degradation in the proteosomes, though
some proteins may be degraded by soluble enzymes in the cytosol. The degraded peptides are either
further degraded into amino acids in the cytosol or are transferred to the endoplasmic reticulum (ER).
Of endogenously degraded peptides, some are picked up with transporters associated with antigen
processing (TAPs), which are encoded by TAP1 and TAP2 genes. TAP1 and TAP2 proteins form a
channel on the endoplasmic reticulum that allows peptides to enter the endoplasmic reticulum, the
luminal side of which has class I molecules. Once a suitable peptide is bound to the class I molecule,
the peptide-bound HLA molecule then moves to the plasma membrane and presents itself to other
cells.44
The processing of and peptide-loading of exogenous proteins on class II molecules is primarily
restricted to B cells, dendritic cells, and macrophages. Exogenous proteins are endocytosed into vesicles
that fuse with primary lysosomes which then acquire proteolytic enzymes and form endosomes in which
the proteins are degraded.44 Though they are also assembled on the luminal surface of the endoplasmic
reticulum, unlike class I molecules, class II molecules do not bind with peptides in the ER, but rather
with a protein that prevents premature binding of peptide—the invariant chain. Class II moleculeinvariant chain complexes enclosed in membranous vesicles meet their exogenous proteins upon
interaction with endosomes in the cytosol.44 These two vesicles fuse to form the MHC class II
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compartment, in which exogenous proteins and most of the invariant chain are degraded by proteases.
To separate the part of the invariant chain that is bound to the class II molecule, other class II molecules
(HLA-DM) dislodge the remaining part and free the peptide-binding groove. Once a peptide binds to
the class II molecule, these complexes are then transported to the surface of the cell.44 Cell surfaces
become decorated with as many as 100,000 to 300,000 of each of the class I and class II MHC-peptide
bound complexes. As such, each normal, or uninfected, cell displays self peptides on the order of
hundreds or thousands on its surface. Most peptides are displayed with around 100 copies, whereas
others may present only a few or thousands of copies.44
During T cell development and maturation in the thymus, the immune system develops a tolerance to
―self‖ proteins and thus has the ability to distinguish between ―self‖ and ―non-self‖ proteins and peptides
that are displayed in the context of MHC. In HSCT, it is from the recognition of ―non-self‖ proteins
that: grafts may be rejected by host cells reacting against donor cells, alloreactive donor cells may target
normal tissues of the host, causing GVHD, and/or donor cells may react against host antigens that are
associated with malignancy and disease, conferring a GVT effect.9 Even with a ―perfect‖ HLA match,
due to extensive polymorphism, an immense number of non-HLA antigens, primarily mHAgs, may be
presented to T cells, and subsequently induce alloreactivity involved in either GVHD or GVT effects.
T cell Development
Pluripotent hematopoietic stem cells in the bone marrow give rise to common lymphoid and myeloid
progenitors. It is the common lymphoid progenitors that, after leaving the bone marrow, enter the
thymus and give rise to thymocytes. In the thymus, differentiation of immature thymocytes is mediated
by the integration of intrinsic signals, which are generated downstream of the TCR, and extrinsic
signals, which are obtained from numerous interactions of T cell progenitors with stromal cells and other
thymocytes.46 T cell development in the thymus can be separated into three broad steps: the first
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spanning thymic colonization to T cell commitment; the second proceeding to the divergence of αβ and
γδ lineages; and, the third consisting of αβ and γδ lineage cells completing their differentiation and
acquiring immunological properties.47
The two distinct T cell lineages—αβ and γδ—arise from common precursor cells termed doublenegative (DN) thymocytes (because they lack expression of CD4 and CD8 co-receptors).46 DN cells are
further divided into subsets based on their developmental potential (DN1(a-e), DN2, and DN3(a,b)).
Transition from the DN1 to DN2 stage marks the initiation of gene rearrangement at the TCRβ, TCRγ,
and TCRδ gene loci. Successful rearrangement of the Tcrd and Tcrg genes promotes the assembly of γδ
TCRs. The αβ TCR is preceded by a pre-TCR that is formed when successful recombination of the Tcrb
gene promotes the assembly of a TCRβ-chain, which then pairs with a surrogate TCRα-chain (the
invariant pre-Tα protein).46 The expression of a functional pre-TCR represents the controlled
developmental transition beyond the DN3 stage, and is referred to as the β-selection checkpoint.46 The
β-selection checkpoint is crucial in identifying proper TCR gene rearrangement at the DN3 stage
because nucleotide deletions and additions may be introduced during RAG-mediated recombination,
with most of the rearrangements being out-of-frame and incapable of producing functional protein.47
During the DN3 stage, those cells which express either a pre-TCR or a γδ TCR are rescued from
apoptosis and subsequently undergo thymocyte proliferation and differentiation.46,48 Along with these
β-selection and γδ-selection events, CD5 and CD27 are upregulated and the cells increase in size,
marking the transition from pre-selection DN3a to post-selection DN3b. Next, the αβ T cell lineages
downregulate CD25 and upregulate CD4 and CD8, thus becoming characterized as double-positive (DP)
CD4+CD8+ cells.46 In contrast to the αβ T cell lineage, most of the γδ lineage remain DN.46 At this stage
in DP αβ T cells, Rag genes are re-expressed, initiating TCRα gene rearrangement and promoting the
assembly of the αβ TCR heterodimers.46,48 DP thymocytes are programmed to undergo apoptosis unless
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they receive a ―rescue signal‖ (positive selection) through the ability of their TCR to bind an MHC
ligand with mild avidity.49 During a three day window before programmed cell death, receptor editing
occurs in which sequential rounds of rearrangement of the TCR-α locus occurs, increasing the chance of
successful self-MHC restriction. For DP thymocytes whose TCR interacts poorly with selfpeptide:MHC ligands and are subsequently unable to generate intracellular signaling needed to sustain
viability, they undergo ―death by neglect.‖50 Some thymocytes bind to self-peptide:MHC with high
avidity and as a result, apoptosis is promoted to prevent an autoimmune pathology that would result if
these cells were to exit the thymus and enter the periphery.50 This strong interaction is referred to as
―negative selection,‖ or clonal deletion. In the end, approximately 95% of DP cells fail positive
selection and undergo ―death by neglect.‖ For the roughly 5% of DP cells that are positively selected,
DP maturation to the single-positive (SP) stage (CD4+CD8- or CD4-CD8+) is induced.49
The alloreactivity that characterizes both GVHD and GVT effects represents the cross-reactivity of
TCRs for non-self peptide:non-self MHC complexes. This interaction is influenced by both the bound
peptide and the MHC molecule, and may be categorized into three types: peptide:MHC dependent in
which alloreactive T cells interact strongly with one specific peptide:MHC complex, but not with the
same MHC bound to different peptides; peptide-dependent in which the peptides presented by non-self
MHC differ from the peptides of the host; and peptide-independent in which alloreactive T cells
recognize non-self MHC without a strict peptide requirement.51 Because the majority of our patients
received stem cell grafts from matched HLA-donors, we are primarily interested in the peptidedependent reactivity of TCRs.
TCR rearrangement and the CDR3 region
The somatic assembly of the TCR genes generates a diverse T cell repertoire during thymocyte
development. The four TCR genes—Tcra, Tcrb, Tcrg, Tcrd—are assembled through V(D)J
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recombination, which is a site-specific recombination process that is directed by the lymphoid-specific
recombinase (RAG, comprised of RAG1 and RAG2) and the ubiquitously expressed DNA repair
proteins.48 The RAG proteins generate double-strand breaks at recombination signal sequences (RSSs)
that flank the TCR variable (V), diversity (D) and joining (J) gene segments. These breaks are
subsequently resolved by non-homologous end joining.48 The alpha and gamma loci undergo
recombination between the variable (V) and joining (J) segments. The beta and delta loci undergo
recombination between V and J segments, and further include one of two short diversity (D) segments.52
There are 52 functional Vβ, 2 Dβ and 13 Jβ segments that undergo VDJ rearrangements to generate Vβ
regions.53 The αβ T cells constitute the bulk of T cell populations in lymphoid organs and normally
react to peptides that are presented in the context of MHC class I or class II molecules.47 In contrast, the
γδ T cells are typically not MHC-restricted and seem to be involved in the surveillance of microbial and
non-microbial tissue stress. The specificity of clonally distributed αβ TCRs is diversified through the
random rearrangement of V and J genes at the TCRα locus and V, D, and J genes at the TCRβ locus of
developing thymic T cells. Diversity is further created through random nucleotide insertion and deletion
of a variable number of nucleotides at the VDJ junctional sites (N-regions).53, 54
Greater than 95% of T cells have αβ TCRs.55 The TCR’s recognition specificity for diverse
peptide:MHC complexes is determined by its three complementarity-determining regions (CDRs):
CDR-1, -2, and -3. CDR1 and CDR2 are coded by germline sequences (Vα and Vβ genes), whereas
CDR3 is derived from the V-(D)-J and N-regions made during somatic recombination.52-53 The TCR
interaction with peptide:MHC complexes suggests a common diagonal docking mode, whereby the
CDR1 and CDR2 loops contact the MHC α helices of the antigen binding groove and the more diverse
CDR3 α and β loops interact primarily with the peptide. The CDR3 is the highly polymorphic
recognition site of the TCR that recognizes antigen specificity, and it is for the additional diversity
16

generated at the CDR3 recombination junctions that the CDR3 is capable of recognizing such a vast
number of peptide:MHC complexes.52
By analyzing the variable region of the TCR CDR3 region, we can determine the clonality of T cell
responses, as different CDR3 sizes correspond to different T cell clones.55 Due to the imprecise nature
of combinatorial diversity and the random addition of nucleotides, each T cell clones expresses a unique
CDR3 region of the TCR V.56 Healthy individuals have highly diverse and polyclonal TCR repertoires
that typically express 8 to 10 different sizes for each Vβ CDR3 region separated by 3 nucleotides.53
Oligoclonal and monoclonal TCR repertoires are associated with strong immune responses.52
Oligoclonal expansion of TCR Vβ families is common and often correlates with GVHD.53
Hypothesis/Aims
Because treatment of GVHD is dominated by broad immunosuppression that leaves patients at
greater risk for complications from infections and abrogation of the GVT effect, there is still a need to
develop a method to directly target GVHD-causing T cells while sparing those involved in host defense
and immunosurveillance.57 As GVHD and GVT are both predominantly T-cell-mediated processes,
analysis of patients’ T cell repertoires may elucidate T cell populations involved in the pathogenesis of
these processes. In a cohort of twelve patients who have undergone allogeneic HSCT for various
hematologic malignancies, we performed quantitative RT-PCR (qRT-PCR) and CDR3 spectratyping of
peripheral T cells to identify antigen-driven T cell responses associated with GVHD and/or GVT effects.
Furthermore, by extracting DNA from GVHD biopsy samples, we are able to not only detect T cell
clones at the site of GVHD, but also correlate those at the site of disease with those identified in the
peripheral blood.
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Materials and Methods

Patients
Twelve patients with hematological malignancies (4 with Non-Hodgkin’s Lymphoma, 5 with
multiple myeloma, 2 with chronic lymphocytic leukemia, and 1 with prolymphocytic leukemia) who
underwent allogeneic hematopoietic stem cell transplantation (HSCT) were included in this study.
Table 1 outlines patient characteristics and Figure 1 depicts the treatment schedule. Also included in the
study was data from the patients’ respective donors in order to compare the T cell repertoire of the
patients relative to their donors at various time points post-HSCT. Donor peripheral blood CD34+ stem
cells (D) were collected at the time of transplant, from which we collected samples, and peripheral blood
samples from recipients were collected prior to and at various time points after transplantation: R
(recipient) denotes pre-transplant before the start of the conditioning regimen; R2 denotes 3 months after
HSCT for all patients, except for Patients 5, 11, 13, and 14, in which R2 denotes time of GVHD onset;
R3 denotes one year post-transplantation for the four patients without GVHD (Patients 3, 4, 7, and 12)
and either the time of GVHD onset (Patients 6, 8, 9, 10) or 3 months post-transplantation (Patients 11,
13, and 14) for the patients who developed GVHD; R4 denotes one year post-transplantation in the
GVHD group (Patients 6, 8, 9, and 11), times of active GVHD for Patients 13 (6 months post-transplant)
and 14 (4 months post-transplant), and time of relapse for Patient 10 (10 months post-transplant); R5
denotes one-year post-transplant for Patient 13 and Patient 10 (R5 is also post-DLI for Patient 10);
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Patients 5 and 14 do not have one-year samples, as both expired prior to this time. Patient 10 also has an
R6 sample that is roughly 22 months post-HSCT and represents time of remission and re-establishment
of GVHD post-DLI treatments that were roughly 2 and 11 months prior to R6. Patient outcomes are
outlined in Table 2, with regards to onset and treatment of GVHD. All patients were informed of the
purpose for the study and agreed to participate. This study was approved by the VCU Institutional
Review Board for the collection of donor CD34+ stem cells and peripheral blood samples from patients
undergoing HSCT at VCUHS, at the time points aforementioned.
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Figure 1:

Figure 1. Treatment regimen for patients undergoing allogeneic HSCT. The treatment regimen
consisted of rabbit anti-thymocyte globulin (ATG) (doses between days -9 and -7) and 450 cGy total
body irradiation in three fractions on days -1 and 0. Patients were randomized as to which ATG dose
they would receive. GVHD prophylaxis with tacrolimus is denoted by the light blue taper (day -3 to
120) and with mycophenolate mofetil (MMF) denoted by the dark blue bar (day 0-30). MRD: matched
related donor; MUD: matched unrelated donor.
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Table 1. Patient characteristics.

MM: multiple myeloma; NHL: non-Hodgkin lymphoma; CLL: chronic lymphocytic leukemia; PLL:
prolymphocytic leukemia; PR: partial response; CR: complete response; MRD: matched related donor;
MUD: matched unrelated donor; HLA code translation for WTR: 01/06/18
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Table 2. Patient outcomes following HSCT.

*T cell chimerism
Patients

Days postHSCT
R2/R3/R4

Patients’
outcome/day
of GVHD
post-HSCT

Treatment for
GVHD

R2

R3

3

11%

0

88/ 365/ NA

No relapse/
No GVHD

NA

4

51%

8%

90/ 322/ NA

No relapse/
No GVHD

NA

7

52%

63%

85/ 298/ NA

No relapse/
No GVHD

NA

12

9%

0%

94/ 356/ NA

No relapse/
No GVHD

NA

5

0

0

89/ NA/ NA

No relapse
GVHD/89

Steroids/ ECP

6

0

0

90/ 148/ 372

No relapse
GVHD/148

Tac/steroids/ ECP

8

2%

3%

79/ 123/ 363

No relapse
GVHD/123

Tac/steroids

9

2%

1%

81/ 120/ 362

No relapse
GVHD/120

Tac/steroids

10

0

0

102/ 172/ 291

Relapse/291
GVHD/160

Steroid topical

11

0

0

54/ 87/ 364

No relapse
GVHD/54

Tac/steroids/rituxan

13

0

0

65/ 96/ 141

No relapse
GVHD/65

Steroid topical

14

0

0

66/ 97/ 129

No relapse
GVHD/66

Tac/steroids/rituxan

Days
postHSCT
death

162

404

171

Percentages indicate the proportion of T cells that are not from the engrafted donor T cells (recipient T
cells). ECP: extracorporeal photophoresis; Tac: tacrolimus.
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Table 3. Cell counts of donor stem cell grafts.

Patient

CD3 x 10^8/kg

3
4
7
12
5
6
8
9
10
11
13
14

3.54
2.31
5.54
1.26
5.68
1.66
3.72
2.86
3.53
11.35
0.43
1.5

CD34 x
10^6/kg
6.52
6.8
6.81
7.99
2.05
5.16
7.45
6.23
3.43
5.13
1.9
4.96

CD3+ counts are 10^8/kg of recipient weight. CD34+ counts are 10^6/kg recipient weight. Patients 3,4,
7, and 12 are GVHD-free and Patients 5, 6, 8-11, 13 and 14 developed GVHD.
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T cell isolation and mRNA Extraction
Recipient blood samples were taken at the time points described above (R-R5), diluted with a 1:1
salt solution, and subsequently layered on Ficoll-Paque™ Premium (GE Healthcare) for density
gradient centrifugation and isolation of mononuclear cells (according to manufacturer’s protocol).
These cells, after washing, were cultured in RPMI medium containing 0.1% autologous serum for 2
hours at 37°C and non-adherent cells were collected. CD3+ cells were isolated using the EasySep®
Negative Selection Human T cell Enrichment Kit (Stem Cell Technologies) according to
manufacturer’s protocol. Subsequently, isolated CD3+ T cells were used for RNA extraction using
Trizol (Invitrogen). For donors, RNA was extracted from peripheral blood CD34+ stem cells. We
determined that un-fractionated CD34+ stem cells still had a high yield of CD3+ T cells in comparison
to CD3+ fractions isolated using a T cell enrichment kit (Figure 2). Therefore, the T cell enrichment kit
was only used for recipient samples, and we proceeded directly to culturing donor CD34+ stem cells in
serum-free medium at 37oC for 2 hours and collected non-adherent cells.

Figure 2
Unfractionated
CD34+ cells

CD3+ fraction

CD3ε

GAPDH

Figure 2. CD3+ fractions in un-fractionated CD34+ stem cells and in isolated CD3+ cells. PCR
products on a 1% agarose gel showing CD3+ cells in un-fractionated CD34+ cells and in T cells isolated
using a negative selection T cell enrichment kit (CD3+ fraction). GAPDH is shown as a control.
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RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer’s protocol.
Next, DNase treatment was performed using RQ1 RNase-free DNase (Promega, according to
manufacturer’s protocol) to digest DNA contamination. Double-stranded cDNA was prepared from 1μg
of total RNA using the SuperScript™ II reverse transcriptase (Invitrogen) with a dT18 oligonucleotide
primer. The cDNA synthesis was completed at 42°C for 2 hours.
Quantitative RT-PCR
Using reverse primers for 23 functional TCR V58 families and one forward primer for the constant
region of the TCR V(Table 4), qRT-PCR was performed for amplification of the CDR3 region using
SensiMix™ SYBR & Fluorescein Kit (BIOLINE) and BioRad’s CFX96 Real-Time PCR Detection
System. Reaction mixtures of 20μl were prepared according to manufacturer’s protocol and 5μl of 30times diluted cDNA were used as a template. Thermo-cycle conditions consisted of initial denaturation
at 95°C (10 min. each), followed by 40 cycles at 95°C (15 s) and 60°C (1 min.). The fluorescent data
was acquired during each extension phase. After 40 cycles, a melting curve was generated by slowly
increasing the temperature from 60°C to 95°C, while the fluorescence was measured. Amplification of
CD3ε fragments with specific primers (forward 5'-CGTTCAGTTCCCTCCTTTTCTT-3', reverse-5'GATTAGGGGGTTGGTAGGGAGTG-3'),59 was used as a normalization control to quantify the
relative expression of different TCR V families. The expression of each V family in recipients was
compared to that of their donors to demonstrate the change in the level of mRNA. A constant donor
sample was used as a control to be able to compare multiple experiments.
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Statistical consideration
A 1-fold increase in expression of the recipients’ V over their donors’ V was used as an arbitrary
cutoff used to distinguish meaningful increases in TCR V. Since the CD3ε subunits were used for
normalization and there are two CD3ε subunits and one CDR3 region associated with each TCR, the
amount of CD3 template was twice as much as that of each TCR V template. Therefore, a 1-fold
increased expression of a given V over CD3 may indicate T cell activation.
Spectratyping analysis of the CDR3 region
PCR products were prepared using 5μl 30-times diluted cDNA and a 20μl PCR master mix
containing 1X PCR Buffer, 1.5 mM MgCl2, 2.5 units of Velocity DNA Polymerase (Bioline), 1 μM Vspecific primer, and 1 μM of a FAM-tagged primer specific for the constant region of TCR (Table 4).
PCR conditions were run as follows: 94C (5 min.), 94C (30s), 60C (30s), 72C (1 min.) for 35 cycles
followed by 10 min. extension at 72C.
PCR products were analyzed at Roswell Park Cancer Institute using an ABI Prism 3130 capillary
sequencer followed by fragment length analysis of the CDR3 region with GeneMapper® software.
Spectratyping results were analyzed with PeakScanner™ Software v1.0 from Applied Biosystems.
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Table 4. TCR V primers.

Degenerate bases: M = A/C; Y = C/T; R = A/G; K = T/G.
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DNA Extraction
Paraffin-embedded biopsy samples from the site of GVHD were available for Patients 5, 6, 8, and
11. DNA extraction methods were previously described by Fan and Gulley.60 From five 5µm thick
sections, paraffin was dissolved using xylene washes. Xylene was was removed with ethanol washes
and ethanol was evaporated in a dry heat block at 55°C. A Proteinase K solution (20mg/mL) in TEN
buffer was added to the samples (100-150µL) and the samples were incubated at 55°C for at least 3
hours. To inactivate the Proteinase K, samples were incubated at 95°C for 10 minutes. Tissues were
pelleted in eppendorf tubes and the supernatant was removed for use as template in PCR reactions. In
order to check quality of DNA, PCR using primers specific for GAPDH (forward 5'ATTGCCCTCAACGACCACTTTG-3', reverse-5'-TTGATGGTACATGACAAGGTGCGG-3')61 was
run. PCR reactions were run for those V families in which both increased expression and
oligoclonality were demonstrated in qRT-PCR and spectratyping, respectively. The primers used are
the same as those outlined in Table 3, without a FAM-tag on the primer for the constant region of the
TCR. PCR products were run on a 1% agarose gel to identify those V families that could be identified
at the site of GVHD.
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Results

TCR V families 4, 11, and 23 are associated with GVHD.
Using qRT-PCR, we looked at the expression of 23 TCR V families in patients relative to that of
their donors in order to identify changes in the T cell repertoire following allogeneic HSCT. As shown
in Figure 3, we identified TCR V families 4, 11, and 23 as those which demonstrated increased
expression in multiple patients with GVHD (with the exception of increased expressions in Patient 12,
who did not develop GVHD). TCR V4 was increased in recipients, relative to their respective donors,
at the time of GVHD in Patients 5, 6, 8, and 10. TCR V11 was increased in Patients 5, 8, 9, 10 and
13, and TCR V23 was increased in Patients 5, 9, 10, 11, and 13, all at their respective times of GVHD.
In a few instances, an increased expression was also seen at the time point prior to the clinical
manifestation of GVHD, suggesting that T cell clones involved in the pathophysiology of GVHD may
be detectable in the blood prior to diagnosis of the disease. This was seen in Patients 8 and 10 at R2 in
V4, in Patients 8 and 9 at R2 in V11, and in Patient 9 at R2 in V23.
Increased expression of T cells is due to either antigen-specific responses or homeostatic
proliferation. In order to determine if TCR Vfamilies 4, 11 and 23 were antigen-driven, and
potentially temporally associated with the incidence of GVHD, we performed spectratyping analysis of
the CDR3 region. Correspondingly, for V4, spectratyping analysis demonstrated oligoclonality in
Patient 5 and monoclonality in Patients 6, 8, and 10 at their respective times of GVHD (Figure 4a).
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Oligoclonality was also seen at R2 in Patients 8 and 10, as expected by their corresponding increases in
qRT-PCR at both R2 and R3 (Figure 3, 4a), which suggests that clonotypes involved in GVHD may be
detectable prior to clinical diagnosis. Patient 6 demonstrated monoclonality at R2 when there was not
an increased expression of V4, and this clone also mirrored that seen in the donor and at R4,
suggesting that it may have been an antigen-experienced T cell population (Figures 3, 4a). The clone
seen at time of clinical diagnosis of GVHD (R3) was different from these other timepoints, suggesting
that it may have emerged in a temporal fashion in association with the onset of GVHD (Figure 4a).
Patient 6’s GVHD was still being treated at one year post-HSCT (R4), so it was expected that the same
clonotype size would persist, though the clone at this time coincided with that seen in the donor as well
as in the recipient prior to GVHD. A possible explanation could be that the clonal population that
emerged at R3 did coincide with onset of acute gut GVHD, but that the severity of the disease was
greatly diminished at R4, such that the clonal population was no longer actively proliferating. With
regards to Patient 10, there was a continuation of clonality after the timepoint of GVHD (R4), and since
GVHD was not wholly resolved at this time (10-months post-HSCT), the continuation of a GVHDassociated clone was expected.
Spectratyping anaylsis of TCR V11 showed monoclonality at the time of GVHD in Patients 5, 8, 9,
and 10 (Figure 4b). (Due to sample limitations there is no spectratyping analysis of Patient 13.)
Patients 8 and 9 also demonstrated increased expression and monoclonality at the timepoint prior to
GVHD-onset (Figures 3, 4b), and since both patients were still on GVHD prophylactic
immunosuppression at R2, the oligoclonality may be due to the emergence of the GVHD-specific
clonotypes early-on during lymphopenia in which peripheral expansion is promoted in efforts to reestablish the T cell repertoire. This further suggests that the alloreactive clonotypes may be detected
prior to clinical manifestation of GVHD, or they may represent restoration of a limited T cell
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population. For Patient 10, there was oligoclonality prior to GVHD (R2), which mirrored the donor’s
repertoire and there was no increased expression of V11 at this time, so it may be representative of
delayed thymopoiesis as the thymus may be damaged by conditioning regimens and its function is
greatly reduced after the involution of the thymus during puberty.62 A different clonotype emerged at
the time of GVHD in Patient 10 (R3), suggesting the temporal association of the clonotype with the
onset of GVHD (Figure 4b). However, Patient 10’s GVHD was not wholly resolved at R4, and
polyclonality was restored at this time. This suggests that if the clonal population at R3 was GVHDspecific, it may have been one of a group of V families involved in GVHD pathogenesis in this
patient, as there were no other clinically noted infections or complications at R3 with which to associate
the clonal population.
Similarly for V23, oligoclonality was also detected at the time of GVHD in Patients 5, 9, 10, and
11 (Figure 4c). For Patients 5, 10, and 11, oligoclonal populations emerged at the time of GVHD in
parallel with the increased expression of V23 at these times. Neither Patient 10 nor 11 had complete
resolution of GVHD at R4, and there was not a complete restoration of polyclonality at these times,
further suggesting the potential role of these clonal populations in mediating GVHD. In Patient 9, an
increased expression of V23 started to emerge prior to GVHD (R2) and continually increased at the
time of GVHD (R3) and at one-year post-HSCT (R4), with monoclonality at all times. Interestingly,
Patient 9’s GVHD was clinically resolved at R4, suggesting that this clonotype may not have been
involved in GVHD as it’s highest expression was seen after disease occurrence was no longer clinically
noted, or that the emergence of another clone was detected over that of the GVHD-associated clone. It
is also possible that this clonal population could have been involved in GVT effect since the increased
expression persisted beyond temporal association with GVHD. Since a continued increase in
expression was not common beyond the clinical resolution of GVHD in our patients, this may be an
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example of how to exclude certain clonal populations from their potential roles in the pathophysiology
of GVHD. Because qRT-PCR only amplifies CDR3 regions irrespective of VDJ rearrangements, we
will use high throughput sequencing to determine the specificity of the T cell clones. With regards to
Patient 11, the oligoclonality that was seen at the onset of GVHD (R2) persisted through one-year postHSCT (R4), and as GVHD was not clinically resolved at R4, the persistence of a GVHD-associated
population was expected. Though the qRT-PCR expression of V23 was lower at R4, the severity of
the disease may have been minimal at this point. Furthermore, Donor 11 also demonstrated
oligoclonality, and the clonal populations seen in Patient 11 mirrored those of the donor, suggesting
another possible explanation for the oligoclonality being that the clonotypes may be antigenexperienced with clonality persisting due to delayed thymopoiesis.
For controls, we also performed spectratyping for patients who did not demonstrate increased
expression relative to their donors in order to demonstrate that oligo- and mono-clonality was
associated with antigen-driven T cell responses. The controls used were: Patient 9 for V4, Patient 11
for V11, and Patient 6 for V23 (Figures 3, 4a-c). Polyclonality is seen as a Gaussian distribution of
CDR3 lengths, and is a result of the random insertion of nucleotides during VDJ rearrangement in T
cell development.62 Though spectratyping of control samples was not always perfectly Gaussian (may
have looked somewhat aberrant, particularly earlier-on after HSCT), there was still a distinction to be
made based on sharp oligo- and mono-clonal peaks that were antigen-driven versus non-antigen-driven
T cell populations. Because thymopoiesis is delayed after HSCT, restoration of normal polyclonal T
cell repertoires is often greatly delayed until naïve CD4+ subsets are restored.62
From the cohort of GVHD patients, 5 out of 8 had GVHD defined as acute—Patients 5, 6, 9, 13, and
14—with Patients 8, 10, and 11 having cGVHD. Based on qRT-PCR and spectratyping data above for
Vs 4, 11, and 23, we saw no difference in these V families being more representative of chronic or
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acute GVHD, as clonally-driven T cell populations were identified in both GVHD types. Patients 5 and
13 had GVHD of the skin and gut, Patient 6 had delayed acute onset of the gut, and Patient 9 had acute
onset for GVHD of the skin (chronic after day 100). Patient 14 had aGVHD of the skin and late-onset
acute grade IV gut GVHD. Patients 8, 10, and 11 had cGVHD of the skin. Patient 6 only demonstrated
increased expression and oligoclonality of V4, suggesting that Vs 11 and 23 may be more specific to
GVHD of the skin, as all other patients with increased expressions and oligoclonality for these V
families had skin GVHD.
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Figure 3:

Figure 3. qRT-PCR analysis demonstrates increased expression of TCR V families 4, 11, and 23
in more than one patient with GVHD. Peripheral T cells from recipients (R2-R5) were compared to
their respective donors (D) at 90 days after HSCT (R2 for No GVHD group, and GVHD Patients 6, 810), time of GVHD (R2 for Patients 5, 11, 13, 14; or R3 for Patients 6, 8-10), one-year post-HSCT (R3
for No GVHD group, R4 for GVHD group except for Patients 10 and 13; R5 for Patients 10 and 13), or
at time of relapse (R4 for Patient 10). Expression of all TCR V families was normalized to CD3.
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Figure 4:

a)

Figure 4. Spectratyping analysis of the CDR3 region of TCR V families with increased
expression in more than one patient with GVHD. a) Spectratyping analysis of V4 - Patients 5, 6, 8,
10. D and R are donor, and recipient, respectively, before HSCT. R2 denotes 90 days post-HSCT for
all patients except for Patients 5 and 11, for which R2 denotes time of GVHD. R3 is time of GVHD
(Patients 6, 8-10) or 90 days post-HSCT (Patient 11). R4 is one-year post-HSCT, with the exception of
Patient 10, for which R4 denotes time of relapse (10 months post-HSCT). A control is also shown
(based on low qRT-PCR expression) to demonstrate that increased expression corresponds to the monoor oligoclonality that is seen at the time of GVHD. ND: no data.
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Figure 4b:

Figure 4b) Spectratyping analysis of V11 - Patients 5, 8-10. D and R are donor, and recipient,
respectively, before HSCT. R2 denotes 90 days post-HSCT for all patients except for Patients 5 and 11,
for which R2 denotes time of GVHD. R3 is time of GVHD (Patients 6, 8-10) or 90 days post-HSCT
(Patient 11). R4 is one-year post-HSCT, with the exception of Patient 10, for which R4 denotes time of
relapse (10 months post-HSCT). A control is also shown (based on low qRT-PCR expression) to
demonstrate that increased expression corresponds to the mono- or oligoclonality that is seen at the time
of GVHD. ND: no data.
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Figure 4c:

Figure 4c) Spectratyping analysis of VPatients 9-11. D and R are donor, and recipient,
respectively, before HSCT. R2 denotes 90 days post-HSCT for all patients except for Patients 5 and 11,
for which R2 denotes time of GVHD. R3 is time of GVHD (Patients 6, 8-10) or 90 days post-HSCT
(Patient 11). R4 is one-year post-HSCT, with the exception of Patient 10, for which R4 denotes time of
relapse (10 months post-HSCT). A control is also shown (based on low qRT-PCR expression) to
demonstrate that increased expression corresponds to the mono- or oligoclonality that is seen at the time
of GVHD. ND: no data.
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TCR V families 9, 16, and 20 are commonly associated with GVT response in GVHD-free patients.
Since GVT effects are predominantly recognized as T-cell-mediated processes in which donor T
cells recognize genetic disparities within recipients, we wanted to see if V families of increased
expression in patients without GVHD were antigen-driven, and subsequently potentially involved in
GVT responses. As shown in Figure 5, TCR V9 was associated with an increased expression in all
four patients without GVHD (3, 4, 7, and 12). Correspondingly, oligoclonality was seen in Patients 3,
4, and 7, at three months (R2) and one year (R3) post-HSCT for Patients 3 and 4, and at one year postHSCT for Patient 7 (Figure 6a). (Due to sample limitations, there is no spectratyping analysis for
Patient 12.) Patient 6 was used as a control for V9 (Figures 5, 6a), which showed oligoclonality at R2,
though this was not at the time of GVHD and polyclonality emerged in subsequent timepoints,
suggesting that the increased expression and clonality seen at R2 may be associated with either
homeostatic proliferation of a limited T cell population or reactivity with residual disease. Patient 8 is
also shown as a control for low expression of V9, but this patient demonstrated monoclonality from
R-R4, which was expected as a result of the continued immunosuppressive treatments this patient was
receiving (this trend was also seen for Vs 2, 3, 7, and 17 in this patient).
TCR V16 showed increased expression in Patients 3 and 4 (Figure 5) and oligoclonality at three
months (R2) and one year (R3) post-HSCT in both patients (Figure 6b). Patients 7 and 9 were used as
controls from the GVHD-free and GVHD groups, respectively. Though Patient 7 demonstrated low
expression of V16 relative to the donor, oligoclonality was seen at three months (R2) and one year
(R3) post-HSCT, suggestive of the delayed thymopoiesis that is common in older patients, as there
were minor clonal populations in addition to the major clonotype, and since an antigen-driven response
should have shown an increased expression in qRT-PCR (Figures 5, 6b). Patient 9 demonstrated more
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polyclonal expression, which was expected as a control (Figure 6b), and though the clonality was not a
―perfect‖ Gaussian distribution, it was still reasonably so considering that complete return of normal T
cell repertoires is delayed by the slower rate of the re-establishment of thymopoiesis after HSCT.
TCR V20 expression was increased in Patients 3, 4, and 12 at three months (R2) and one year (R3)
post-HSCT (Figure 5). Patient 3 demonstrated oligoclonality at three months and one year post-HSCT,
and Patient 4 demonstrated monoclonality at one year post-HSCT (Figure 6c). The polyclonality that
was seen at three months in Patient 4 was likely due to homeostatic proliferation, as there was an
increased expression of V20 at this time. Patients 7 and 10 were used as controls for V20, from the
GVHD-free and GVHD groups, respectively. As shown in Figure 6c, V20 was not detected in Patient
7 at time R just prior to transplant, which was not surprising as evidenced by the extremely low qRTPCR expression (Figure 5). Polyclonality was seen at three months post-HSCT (R2) in Patient 7, as
expected by low expression. Oligoclonality was seen in Patient 7 at one year post-HSCT (R3), and
though the qRT-PCR expression was lower than that of the donor, this clonality could have been due to
an antigen-driven response that happened some time prior to R3. Such instances in which
oligoclonality is detected without a corresponding increased expression demonstrate the limitations of
qRT-PCR in amplying CDR3 regions without being able to distinguish between different VDJ
rearrangements. For the other control, Patient 10 demonstrated a skewed repertoire at R2 (Figure 6c),
but this could be due to delayed thymopoiesis as the patient was still under immunosuppression. Also,
there was an increased expression in Patient 10 at R3 (Figure 5), though it could have been due to
homeostatic proliferation as the T cell population at R3 was polyclonal.
Moreover, with regards to the GVHD-free patients, Patients 4 and 7 had mismatches of the DQB1
allele: Patient 4 (0201)/Donor 4 (02GM); Patient 7 (0302)/Donor 7 (0301) (Table 1). It is possible that
GVT-responses were alloreactive against these mismatches, though the increased expression and
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oligoclonality of Vs 9, 16, and 20 were not exclusively seen in these two patients. Patient 3 was
homozygous for the DQB1 0602 allele, which Donor 3 also had, though Donor 3 also had a DQB1
0503 allele. However, because the patient does not express the 0503 allele, it would be considered a
mismatch in a host-versus-graft response and not in a GVT response since the donor expresses the
DQB1 0602 allele as well.
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Figure 5:

Figure 5. qRT-PCR analysis demonstrates increased expression in TCR V families 9, 16, and 20
in more than one patient without GVHD. Peripheral T cells from recipients (R2-R5) are compared to
their respective donors (D), as previously described, with expression of all TCR V families normalized
to CD3.
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Figure 6:

6a)

Figure 6. Spectratyping analysis of the CDR3 region of TCR V families with increased
expression in more than one patient without GVHD. a) Spectratyping analysis of V9 - Patients 3,
4, and 7 show monoclonality at the times of increased qRT-PCR expression (at R2 and R3 for Patients 3
and 4, and at R3 for Patient 7); Patient 6 is shown as a control (low qRT-PCR expression). D and R are
donor, and recipient, respectively, before HSCT. R2 denotes 90 days post-HSCT. R3 is one year postHSCT in Patients 3, 4, and 7, and R3 also denotes the time of GVHD in controls 6, 9, and 10. R4 is oneyear post-HSCT for Patients 6 and 9, and ten months post-HSCT for Patient 10. ND: no data.
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Figure 6b:

ND

Figure 6b. Spectratyping analysis of V16 - Patients 3 and 4 demonstrate monoclonality at the time of
increased expression (R2 and R3). Patients 7 and 9 are shown as controls of patients without and with
GVHD, respectively. D and R are donor, and recipient, respectively, before HSCT. R2 denotes 90 days
post-HSCT. R3 is one year post-HSCT in Patients 3, 4, and 7, and R3 also denotes the time of GVHD
in controls 6, 9, and 10. R4 is one-year post-HSCT for Patients 6 and 9, and ten months post-HSCT for
Patient 10. ND: no data.
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Figure 6c:

ND

Figure 6c. Spectratyping analysis of V20 - Patient 3 shows oligoclonality at R2 and R3, and Patient 4
shows monoclonality at R3. Patients 7 and 10 are controls, without and with GVHD, respectively. D
and R are donor, and recipient, respectively, before HSCT. R2 denotes 90 days post-HSCT. R3 is one
year post-HSCT in Patients 3, 4, and 7, and R3 also denotes the time of GVHD in controls 6, 9, and 10.
R4 is one-year post-HSCT for Patients 6 and 9, and ten months post-HSCT for Patient 10. ND: no data.
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TCR V families 5 and 24 are privately associated with GVT response in Patient 3.
TCR V families 5 and 24 demonstrated increased expression in Patient 3, suggesting a potential role
in a GVT response in this patient. As shown in Figures 7a and 7b, there was an increased expression
and a skewed clonal population of V5 in Patient 3 at one year post-HSCT (R3). The spectratyping at
R3 mirrored that at three months post-HSCT (R2), yet R2 did not have a corresponding increased
expression, which may have been due to delayed thymopoiesis. The spectratyping at R3 may then have
been due to an increased expression of the dominant clone (noted at 435bp in Figure 7b) with a
corresponding reconstitution of the T cell repertoire. Since R3 represents one year post-transplant, the
increased expression was less likely due to homeostatic proliferation as this predominantly occurs
during lymphopenia early-on after transplantation. Regardless, caution should still be used with skewed
populations like the one seen in Patient 3, because the distinction between oligoclonal antigen-driven
responses and skewed repertoires is less clear than if there is a strong monoclonal peak with a greater
increase in qRT-PCR expression (less than 1-fold increase in V5 at 3R3 if considering the lower end of
the error bar). Figure 7a also shows an increased expression of V5 in Patient 12, but conclusions as to
what this expression might correspond to will be determined in future studies (for limitations previously
addressed). Patient 4 was used as a control for V5 and showed polyclonality as expected.
As shown in Figures 7c and 7d, Patient 3 also showed increased expression and oligoclonality in
V24, though the dominant clones seen (at R2 and R3) in Figure 7d mirrored the major clonotype of
Donor 3’s T cell population.
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Figure 7:
7c)
7a)

7b)

7d)

Figure 7. TCR V families 5 and 24 are associated with GVT response in a patient-specific
fashion. a) qRT-PCR analysis shows an increased expression of V5 in GVHD-free Patients 3 and
12. b) Spectratyping analysis of V5 for Patient 3 corresponds to oligoclonality. Patient 4 is shown
as a control. c) qRT-PCR analysis of V24 shows increased expression of V24 in Patient 3. d)
Spectratyping analysis of V24 shows monoclonality in Patient 3 at R2 and R3. Patient 4 is shown
as a control. Time points are as previously described.
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Increased expression of TCR V families 2, 3, 7, 8, 12, 15, and 17 are shared by both GVHD and
GVHD-free patients.
In addition to identifying V families that were increased in either the GVHD or GVHD-free patient
groups, we also wanted to see if certain V families were commonly associated with patients in both
groups. As shown in Figure 8, TCR V families 2, 3, 7, 8, 12, 15, and 17 show increased expression in
multiple recipients, respective to their donors, in both the GVHD-free and GVHD groups.
TCR V2 was increased in all GVHD-free patients as well as in GVHD Patients 6, 9, 10, 11, and 13.
As shown in Figure 9 with regards to V2, GVHD-free Patients 3 and 7 showed oligoclonality at one
year post-HSCT (R3), as expected based on their respective qRT-PCR data. The clonality in Patient 3
followed a similar trend to that seen in this patient for V5 in which the same clonality was seen at R2
and R3 though there was only a corresponding increased expression at R3. Also, the oligoclonality was
borderline skewed, again demonstrating the fine line between antigen-driven peaks and the typical
aberrant restoration of normal T cell repertoires in patients following HSCT. The clone seen at one
year post-HSCT (R3) in Patient 7 mirrored that seen in the patient before transplant, which may
represent continuation or reactivation of that antigen-experienced population, as Patient 7 had 63%
recipient T cell chimerism at R3. Patients 6, 10, and 11 all showed a major clone over a polyclonal
background, demonstrating restoration of the V2 repertoire during homeostatic proliferation. Because
there was no retention of the oligoclonality from the time of GVHD onset (R2) at R3 in Patient 11, the
skewed population at R2 could also be explained by homeostatic proliferation with delayed
thymopoiesis since a GVHD-associated clone should have continued from R2 to R4, as GVHD was not
wholly resolved at R4. Though Patient 9 demonstrated increased expression at R3, there was a
polyclonal population, suggesting that the increased expression was due to homeostatic proliferation.
An oligoclonal population emerged at R4, though there was no corresponding increased expression,
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demonstrating the limitations of qRT-PCR in being unable to determine the proportions of specific
CDR3 sequences, as opposed to amplifying individual CDR3 sequences. Patients 4 and 8 were run as
controls for V2. Patient 4 demonstrated polyclonality, as expected. Patient 8 demonstrated
oligoclonality from R2-R4, which as aforementioned was common, as this patient was still being
treated with immunosuppressive therapies that hindered reconstitution of a normal T cell repertoire.
For TCR V3, GVHD-free Patients 3, 7, and 12 and GVHD Patients 6, 11, and 13 showed increased
expression (Figure 8). Patient 3 demonstrated oligoclonality at three months (R2) and one year (R3)
post-HSCT (Figure 10) with minor clones in addition to the major clone, representing an oligoclonal
expansion over a polyclonal background. Patient 7 demonstrated oligoclonality only at R2, which may
be due to the mixed chimerism (52% recipient T cells), as this clone mirrored that of the patient at time
R prior to HSCT (Figure 10). Though there was also increased expression at one year post-HSCT (R3)
in Patient 7 (Figure 8), the clone mirroring that from R2 was less dominant as the spectratyping was
more polyclonal (Figure 9), which may be explained by homeostatic proliferation and initial reestablishment of thymopoiesis. Retention of the clone from R2 at R3, along with the emergence of
other clones at R3, may also demonstrate mixed chimerism showing a major clone from either the
patient or donor and a polyclonal population from the other (Patient 7 had 63% recipient T cell
chimerism at R3). With regards to the GVHD patients, oligoclonality was seen in Patients 6 and 11 at
their respective times of GVHD (Figure 10). Because Patient 6 was still being treated for GVHD at one
year post-HSCT (R4), the continuance of the clonal population from the time of GVHD onset (R3) at
R4 was expected. Patient 11 showed oligoclonality of three dominant clones at R2 and R3, as expected
based on increased expression (Figures 8, 10), and though the onset of GVHD is at R2, the patient was
still being treated for GVHD at R3 and R4, so the continued clonality was expected. Furthermore, that
there are potentially three antigen-associated clonal populations in Patient 11, it is possible that they
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were related to GVHD and/or GVT. Patients 4, 8, and 9 are shown in Figure 8 as controls. Patients 4
and 9 demonstrated polyclonality, as expected. Patient 8 showed oligoclonality, which, as
aforementioned, was resultant of continued GVHD treatment, thus hindering the reconstitution of a
diverse T cell repertoire.
Increased expression of TCR V7 was seen in GVHD-free Patient 3 and in GVHD Patients 6, 9, 10,
11, 13, and 14 (Figure 8). As shown in Figure 11, Patient 3 showed oligoclonality at R2 and R3,
suggesting that the increased expression may have been due to an antigen-driven response. Patients 4
and 7 are shown as controls. Though a skewed repertoire was seen at R2 in Patient 4, it may have been
due to delayed thymopoiesis. Patient 7 showed a dominant clone at R2, which mirrored that of the pretransplant clone seen at R, suggesting retention of that clonal population from the patient as there was
52% recipient T cell chimerism at R2. Because this clone was still the major clone seen over the
polyclonal population at R3, this clone may again represent the patient’s mixed chimerism, with the
dominant clone being from either the donor or recipient and a polyclonal population being due to the
other. Patient 6 demonstrated polyclonality at the time of GVHD onset (R3), which was likely a result
of homeostatic proliferation. Furthermore, Patient 6 demonstrated oligoclonality at R2 and R4, though
there were not corresponding increases in expression at these times. This suggests that these clonal
populations may have been involved in GVT responses at either time. Patients 9, 10, and 11 all showed
oligoclonality corresponding to their increased expressions of V7 (Figure 11). The clonality seen at
the time of GVHD onset in Patients 10 (R3) and 11 (R2) continued at R3 and R4, which was not
unexpected, as neither patient had complete resolution of GVHD at R4. Patient 8 was used as a control
from the GVHD group and again demonstrated oligoclonality as a result of immunosuppression. The
donors for Patients 10 and 11 had somewhat skewed T cell populations for V7 at the time of
transplant, which may be representative of antigen-experienced T cell populations. Patients 9, 10, and
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11, as well as Patients 3, 7, and 8, all demonstrated oligoclonality at time R prior to transplant. This
may indicate that the V7 family is associated with common viral or pathogen immunity, as a skewed
repertoire was also seen in Donors 7, 10, and 11. Furthermore, the V7 family may have a more
restricted repertoire based solely on base pair size, as the skewed repertoires were seen throughout the
spectratyping data for V7 both in patients with and without increased expression. This is also implied
in the broader bases of the peaks, which shows a saturation of clones within a given base pair region,
unlike the Gaussian distribution seen in polyclonal populations with major peaks separated by 3
nucleotides.
The TCR V8 family was increased in GVHD-free Patients 4 and 12 and GVHD Patients 5, 10, 11,
and 14 (Figure 8). As shown in Figure 12, Patient 4 showed oligoclonality at times R2 and R3,
indicative of an antigen-driven response. Donor 4 also showed a dominant peak around the same base
pair size as that seen at R2 and R3 in the recipient, indicating that this clone may have been antigenexperienced. If this donor clone was represented in the clonal population demonstrated at R2 and R3, it
may demonstrate the ability for antigen-experienced T cells to recognize non-self peptide:MHC
complexes.63 The human memory T cell population is dominated by reactivities to common DNA
viruses (i.e. – CMV, EBV, HSV), and the possibility of cross-reactivity of antigen-experienced T cells
with foreign peptide:MHC complex is high, despite the rarity of individual cross-reactivities.63 As
shown by Melenhorst et al., antigen-experienced CD4+ and CD8+ T cell subsets are able to recognize
MHC-mismatched APCs.63 Since Patient 4 had an HLA-DQB1 mismatch (Table 1), this clonallydriven population may have been involved in a GVT response through either cross-reactivity of an
antigen-experienced T cell or from direct HLA-dependent recognition. Patient 3 is shown as a GVHDfree control, and though there was slight oligoclonality at R2, it was likely due to the patient still being
under immunosuppressive treatment at R2, as the repertoire became more polyclonal at R3. GVHD
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Patients 5, 10 and 11 showed oligoclonality, as expected by increased expression (Figures 8, 12).
Patient 10 showed a dominant clonotype over a skewed background at the time of GVHD onset (R3).
This clonal population was also seen at R2 and R4, indicating the potential for a GVHD-associated
clone to be detected prior to clinical diagnosis, and the continuance of the clone at R4 was expected as
this patient’s GVHD was not wholly resolved at R4. Patient 11 demonstrated dramatic clonality that
mirrored that of Donor 11. Though Patient 11 did not have any HLA mismatches, these clonotypes
were likely antigen-experienced, and may have been involved in a GVT or GVHD response against
non-self peptide:MHC in a peptide-dependent manner. Patient 6 showed a slight increase in expression
at R2, but the aberrant clonality fits with homeostatic proliferation as opposed to an antigen-driven
response. Patient 8 is shown as a control from the GVHD group, and was predominantly polyclonal as
expected.
As shown in Figure 8, expression of the TCR V12 family was increased in GVHD-free Patients 4
and 12 and GVHD Patients 6, 8, 10, and 13. Patient 4 showed a somewhat oligoclonal population at R2
(Figure 13), but this was likely due to delayed thymopoiesis and homeostatic proliferation, as
polyclonality was completely restored at R3. Patients 6, 8, and 10 all demonstrated oligoclonality at the
time of GVHD as expected based on increased qRT-PCR expression (Figures 8, 12). However, GVHD
was not clinically resolved at R4, and clonality only persisted in Patient 6 at R4, indicative of
continuance of a GVHD-associated clone. Furthermore, the major clonal populations seen in Patients 6
and 10 were the same size (433bp; Figure 12), suggesting a role for a GVT effect to a mHAg that is
restricted to the hematopoietic system. Patients 3 and 11 were used as controls, and both demonstrated
polyclonality as expected.
Continuing through Figure 8, expression of TCR V15 was increased in GVHD-free Patients 3, 4,
and 12 and GVHD Patients 10, 11 and 13. Figure 14 shows oligoclonality in Patient 3 at R2 and R3,
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indicating an antigen-driven response, and Patient 4 was predominantly polyclonal, indicating
homeostatic proliferation. Patients 10 and 11 also demonstrated oligoclonality at the time of GVHD, as
expected. The continuance of clonality from R2 through R4 in Patient 10 may depict the ability to
detect a GVHD-associated clone prior to clinical diagnosis (R3), and since GVHD was not wholly
resolved at R4, this better supports the possibility of this clonal population being associated with
GVHD. The sharp monoclonality seen in Patient 11 mirrored the clonotypes seen in both donor and
recipient before transplant, suggesting that this population may have been antigen-experienced to a
common virus or pathogen. If this clonal population was antigen-experienced, it may have been able to
cross-react with non-self peptide:MHC complexes in a peptide-dependent manner (as there are no HLA
mismatches in Patient 11). Patient 7 is shown as a GVHD-free control and depicted oligoclonality,
which may have been due to both mixed T cell chimerism and retention of the recipient’s clonotype
from R (as discussed previously for this patient) and delayed thymopoiesis. Patient 8 is shown as a
control from the GVHD group, and though there was slight oligoclonality at R2, it was consistent with
delayed thymopoiesis as polyclonality was more evident at R3 and R4.
For the last TCR V family shared by both GVHD-free and GVHD patients in Figure 8, expression
of V17 was increased in GVHD-free Patients 3 and 12 and GVHD Patients 10, 11, and 13. Patient 3
showed oligoclonality at R3 (Figure 15), as expected based on increased qRT-PCR expression.
However, the clonality seen at R3 mirrored that seen at R2 when there was not a corresponding
increase in expression, reiterating the caution in defining certain oligoclonal populations as either
oligoclonally antigen-driven responses or as skewed repertoires resultant of delayed thymopoiesis and
restoration of a normal T cell repertoire. Patient 4 is shown as a control from the GVHD-free group
and demonstrated polyclonality as expected. Patients 10 and 11 demonstrated oligoclonality at their
times of GVHD, R3 and R2, respectively. The clonality demonstrated in Patient 10 persisted from R252

R4, suggesting the ability to potentially identify GVHD-associated T cell populations prior to clinical
diagnosis, and as this patient’s GVHD was not completely resolved at R4, the continuance of this
clonal population was expected. The clonality seen at R2 and R3 in Patient 11 may have been involved
in a GVHD or GVT response. Since Patient 11’s GVHD was still being treated at R4, if the R2 and R3
clonal populations were GVHD-associated, they should have persisted at R4, though they may have
been less prominent if the GVHD was very minimal at that time. Patient 8 is shown as a control from
the GVHD group and demonstrated the same monoclonal trend that was evident in previous V
families, as this patient was under continued immunosuppression. There was also no clonal population
detected in the V17 family for Patient 8 at time R prior to transplant, and as the qRT-PCR expression
was very low at this time, this result was not surprising.
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Figure 8:

Figure 8. TCR V families with increased expression in patients with and without GVHD. qRTPCR analysis of TCR V families 2, 3, 7, 8, 12, 15 and 17 in all patients. Times points are as
previously described.
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Figure 9:

Figure 9. Spectratyping analysis of TCR V2 in patients with and without GVHD. Blue boxes
denote oligoclonality in patients without GVHD at the time of increased TCR V2 expression (R3).
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 6, 10;
and, R2 for Patient 11). Patients 4 and 8 are negative controls based on low qRT-PCR expression of
V2. Time points are as previously described. ND: no data.
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Figure 10:

Figure 10. Spectratyping analysis of TCR V3 in patients with and without GVHD. Blue boxes
denote oligoclonality in patients without GVHD at the time of increased TCR V3 expression (R2 -R3).
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 6, R2 for
Patient 11). Patients 4, 8, and 9 are controls. Time points are as previously described. ND: no data.
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Figure 11:

Figure 11. Spectratyping analysis of TCR V7 in patients with and without GVHD. Blue boxes
denote oligoclonality in patients without GVHD at the time of increased TCR V7 expression (R2 -R3).
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 9, 10;
and, R2 for Patient 11). Patients 7 and 8 are controls. Time points are as previously described. ND: no
data.
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Figure 12:

Figure 12. Spectratyping analysis of TCR V8 in patients with and without GVHD. Blue boxes
denote oligoclonality in patients without GVHD at the time of increased TCR V8 expression (R2 -R3).
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patient 10; and,
R2 for Patients 5 and 11). Patients 3 and 8 are controls. Time points are as previously described. ND:
no data.
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Figure 13:

Figure 13. Spectratyping analysis of TCR V12 in patients with and without GVHD. Blue boxes
denote oligoclonality in patients without GVHD at the time of increased TCR V12 expression (R2 R3). Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patients 6,
8, and 10). Patients 3 and 11 are controls. Time points are as previously described. ND: no data.
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Figure 14:

Figure 14. Spectratyping analysis of TCR V15 in patients with and without GVHD. Blue boxes
denote oligoclonality in patients without GVHD at the time of increased TCR V15 expression (R2 R3). Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patient 10,
R2 for Patient 11). Patients 7 and 8 are controls. Time points are as previously described. ND: no
data.
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Figure 15:

ND

Figure 15. Spectratyping analysis of TCR V17 in patients with and without GVHD. Blue boxes
denote oligoclonality in patients without GVHD at the time of increased TCR V17 expression (R3).
Red boxes denote oligoclonality in patients with GVHD, at the time of GVHD (R3 for Patient 10, R2 for
Patient 11). Patients 4 and 8 are controls. Time points are as previously described. ND: no data.
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DNA extraction from GVHD-biopsy tissues identified specific V families at the site of GVHD.
We next wanted to determine if there was a direct correlation between the levels of T cell clones in
the circulation with those at the site of GVHD. GVHD Patients 5, 6, 8, and 11 had available paraffinembedded biopsy samples from which we were able to extract DNA. We used GAPDH primers to run
PCR reaction to confirm the extraction of DNA from these samples. Figure 14 shows the results of
these PCR reactions for GAPDH, with all products showing bands on a 1% agarose gel around the
300bp region. Patients 5, 6, and 11 had one sample, corresponding to the time of GVHD, which was R2
for Patients 5 and 11, and R3 for Patient 6. Patient 8 had two samples, Sample A corresponding to the
first clinical indications of GVHD onset (R3), and Sample B, corresponding to three months after
Sample A, during active chronic GVHD. We also used a control sample from non-GVHD Patient 4 who
had a biopsy taken around 4 months post-HSCT, which was classified as folliculitis (an infection in the
hair follicles, often caused by bacteria). Based on qRT-PCR and spectratyping, we ran PCR using
primers for those TCR V families that demonstrated both increased expression and oligoclonality in
order to see if we could detect these V families at the site of GVHD. We also ran negative control
PCR reactions based on V families that had low qRT-PCR expression.
Patient 5 demonstrated increased expression and oligoclonality in V families 4, 8, 11, and 23
(Figures 3, 4, 8, 12). PCR products for Vs 4, 11, and 23 were detected at the site of GVHD, as shown
by the PCR product bands on a 1% agarose gel (Figure 17). Control reaction for Vwas detected at
the site of GVHD, though there was polyclonality at this time in the peripheral T cells (Figures 17a,b).
For Patient 6, PCR reactions were run for Vs 2, 3, 4, and 12 because they demonstrated both increased
expression and oligoclonality (Figures 3, 4, 8, 10, 13). From these reactions, Vs 2 and 4 were detected
at the site of GVHD (Figure 18). Vs 6 and 9 were run as negative controls and did not show bands on
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the agarose gel, as expected (Figures 5, 6a, 21a,b).
For Patient 8, because Sample A corresponds to R3 and Sample B is from 3 months after R3 and
therefore does not have a corresponding peripheral T cell sample, we ran PCR products for Sample B
based on our predictions for Sample A. Patient 8 demonstrated increased expression and oligoclonality
in V families 2, 3, 4, 11, 12, 17 (Figures 3, 4, 8-10, 13, 15). From these, Vs 2 and 4 were detected in
both Samples A and B, and V11 was detected in Sample B. V9 was run as a negative control based
on low qRT-PCR expression (Figures 5), though it was detected at the correct size (539bp), and a
smaller second band was detected around the 400bp region (Figure 19) (the second band could be due to
primers binding to homologous sequences in the DNA or to amplification of non-transcribed DNA with
stop codons). Though Patient 8 demonstrated oligoclonality for V9 at all times (R-R4), this could have
been a result of his continued immunosuppression, as the oligoclonality was seen in multiple V
families of low expression throughout his course of treatment. Furthermore, V9 may merely represent
non-clonal T cell populations at the site of GVHD. Since the clonality of the V families detected at the
site of GVHD is not known from our data, we cannot eliminate the various possibilities for these T cells.
For Patient 11, PCR was run for those V families of both increased expression and oligoclonality:
2, 3, 7, 8, 11, 17, and 23 (Figures 3, 4, 8-12, 15). V6 was also run due to its increased expression in the
peripheral blood (Figure 21a). As shown in Figure 20, Vs 2, 3, 6, 15 and 17 were detected at the site of
GVHD. V11 was run as a negative control, and correspondingly no band was detected.
It has been shown that Vs 2 and 6 are common in the healthy skin of adults, so though these V
families may have low expression in the peripheral blood, they may also be common in the skin.64 We
detected V2 at the site of disease in each of our samples that were from skin GVHD (Patients 8 and
11), in which Patient 11 had increased expression and a skewed repertoire (Figure 8, 9), and Patient 8
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demonstrated low expression (Figure 8) and oligoclonality (Figure 9) in the peripheral blood. Low
expression with corresponding oligoclonality was expected for Patient 8, as continued
immunosuppressive treatments hindered the re-establishment of a normal T cell repertoire. With regards
to V6, it was only detected at the site of GVHD in Patient 11, and though there was a slight increase in
qRT-PCR expression in the peripheral blood, polyclonality was seen at this time (Figure 21a,b). To
compare our results to those of Menssen et al. in which Vs 2 and 6 were detected in the skin of normal
healthy adults,64 we ran PCR reactions for the control folliculitis sample, Patient 4, in which V2 was
identified, but not V6 (Figure 22). There was both low expression (Figures 8, 21a) and polyclonality
(Figures 9, 21b) of V2 and 6 in Patient 4, demonstrating that these V families were not actively
involved in antigen-driven responses in the peripheral blood. However, since V2 was identified in the
folliculitis sample from Patient 4, our results suggest that V2 may have been involved in pathogenesis
of folliculitis. This further suggests that V2 may be commonly found in the skin, where it is activated
by local inflammation and/or infections, as it was found in each of our skin GVHD samples as well as
our non-GVHD control. Furthermore, V2 was detected at the site of gut GVHD in Patient 6, in which
there was an increased expression and skewed repertoire (Figures 8,9), and in Patient 5 who
demonstrated low expression and polyclonality (Figures 8, 17b) in the blood. As evidenced in Patients 5
and 6, even if V2 is commonly found in the skin, it may be commonly associated with the T-cellmediated inflammatory response in GVHD, regardless of the tissue involved.
Overall, V4 was identified in three, V11 was identified in two, and V23 was identified in one, out
of the four patients with GVHD biopsies. Patients 5 and 6 had acute GVHD of the gut, whereas Patients
8 and 11 have chronic GVHD of the skin. There was no unique correlation of Vfamilies between
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patients with chronic versus acute, or gut versus skin, GVHD.
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Figure 16:

Figure 16. Extraction of DNA confirmed by GAPDH control. DNA was extraction from paraffinembedded biopsy samples from the site of GVHD, at the time of GVHD. PCR was run with GAPDH
primers as a control to verify extraction of DNA. Patients 5, 6, and 11 have one sample, corresponding
to the time of GVHD, which is R2 for patients 5 and 11, and R3 for Patient 6. Patient 8’s Sample A
corresponds to the first clinical indications of GVHD onset (R3) and Sample B corresponds to three
months after R3, during active chronic GVHD. A control sample was also used from non-GVHD
Patient 4 who had a biopsy about 4 months post-HSCT, which was classified as folliculitis.
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Figure 17:
17a)

17b)

Figure 17. Patient 5 DNA extraction. a) PCR products yielded positive results for TCR Vs 4, 11,
and 23 (indicated in bold) which showed increased qRT-PCR expression and oligoclonality. Control
sample V2 (underlined) was also detected at the site of GVHD, even though there was low expression
and polyclonality in the peripheral blood at this time. Expected sizes of products are shown in each well
corresponding to the respective V families. Results are shown on a 1% agarose gel. b) Spectratyping
of V2 in Patient 5’s peripheral blood sample shows polyclonality at the time of GVHD (R2). ND: no
data.
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Figure 18:

Figure 18. Patient 6 DNA extraction. PCR products yielded positive results for TCR Vs 4 and 2
(indicated in bold), which showed high qRT-PCR expression and oligoclonality. Control sample Vs 6
and 9 were negative (italicized), as expected based on low qRT-PCR expression at the time of GVHD.
Expected sizes of products are shown in each well corresponding to the respective V families. Results
are shown on a 1% agarose gel.
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Figure 19:

Figure 19. Patient 8 DNA extraction. The letters A and B correspond to time point R3 and three
months after R3, both are times of GVHD. There is no corresponding peripheral T-cell sample for the
B sample, so the PCR reactions were chosen for both A and B sample based on qRT-PCR and
spectratyping analyses at the time of R3. PCR products yielded positive results for TCR Vs 2 and 4 for
both A and B and V11 for B (indicated in bold). Control reactions for V9 gave positive results for
both samples A and B (underlined). Expected sizes of products are shown in each well corresponding to
the respective V families. Results are shown on a 1% agarose gel.
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Figure 20:

Figure 20. Patient 11 DNA extraction. PCR products yielded positive results for TCR Vs 3, 17, 15,
2, and 6 (indicated in bold). V11 was run as a negative control (italics). Expected sizes of products are
shown in each well corresponding to the respective V families. Results are shown on a 1% agarose
gel.
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Figure 21:

21a)

21b)

Figure 21. qRT-PCR and spectratyping analysis of V6. a) qRT-PCR. b) Spectratyping. The red
box denotes the time in which V6 was detected at the site of GVHD in Patient 11. ND: No data.
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Figure 22:

Figure 22. DNA extraction from control sample for Vs 2 and 6. V2 yielded positive results
(underlined) and V6 was negative. Results are shown on a 1% agarose gel.
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Patient 10 – Relapse followed by remission and re-onset of GVHD post-DLI treatments
Patient 10 is a unique example of TCR V repertoire at onset of GVHD, resolvement of GVHD,
relapse, and post-DLI remission and GVHD. The course of her clinical events in which we obtained
peripheral blood samples were: 3 months post-HSCT (R2), GVHD-onset 6 months post-HSCT (R3),
relapse 10 months post-HSCT (R4), clinical resolvement of GVHD at one year post-HSCT (R5),
remission and re-onset of GVHD (R6), and DLI treatments one month prior to R5 or two months prior
to R6. DLI is used to induce remission in patients who have relapsed, demonstrating the powerful GVT
effects of donor allorecognition of malignant cells in recipients.16,27,65,66 Furthermore, use of DLI also
carries a risk for post-DLI GVHD,16,27,65,66 as evidenced in Patient 10.
We looked at qRT-PCR and spectratyping data in Patient 10 in order to identify T cell clones that
coincided with relapse (disappearance of GVT-associated clones) and post-DLI remission and GVHD
(emergence of clones). We first looked at V families that were commonly associated with GVHD—4,
11, and 23 (Figures 23, 24a). V4 demonstrated less than 1-fold increase in expression at R2, R3, and
R5, with the same oligoclonality persisting from R2-R4, as previously mentioned, that was likely
associated with cGVHD that may have been detectable prior to clinical diagnosis at R3. After the first
DLI treatment, a second major V4 clone emerged at R5, but was less prominent at R6, suggesting that
it was not involved in GVT or GVHD as clones involved in either effect should have persisted or
emerged at R6. With regards to V11, the strong clonotype at the onset of GVHD (R3) was no longer
evident at R4 suggesting that it may not have been GVHD-specific, as clinical resolution of GVHD was
not identified until R5. Since polyclonality was restored at time of relapse (R4), the disappearance of
the clone from R3 may have been GVT-associated. Also, a new clonotype emerged at R6, suggesting a
role for this T cell population in either GVHD or GVT, as both remission and GVHD occurred postDLI. However, there was low expression of V11 at R6, further suggesting that this clonotype may
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have been site-specific and less detecable in the peripheral blood. For V23, we saw a skewed
repertoire that persisted from R2-R5 that slightly shifted in size at R6, indicating a change in antigenspecificity. Since Patient 10’s first course of cGVHD was clinically resolved at R5, it may be that the
continued clonal population was below clinical detection of GVHD.
We next wanted to look at Vs from the group of V families that were increased in patients with
and without GVHD (Figures 23, 24b). For V2, there was an oligoclonal population over a polyclonal
background from R2-R4, suggesting a role for a GVHD-specific clone. At R5, this clone was no longer
evident, suggesting a role in a GVHD response, as clinical resolution was around R5. At R6, a new
oligoclonal population emerged that may have had a role in either GVHD or GVT. In V7, the peristent
clone from R2-R5 was diminished at R6, at which time a new clone emerged. This clone at R6 mirrored
that of the one in the recipient prior to transplant, suggesting a role in anti-myeloma response. In V8,
the major clonotype that was seen from R2-R4 was no longer present at R5 or R6, suggesting that it may
have been specific for the patient’s first bout of GVHD. V12 showed a similar trend to that of V8.
V15 showed a dominant clone that persisted from R2-R6, though a polyclonal background didn’t
emerge until R5. Since the skin was involved with both the first and second course of GVHD, it may be
that this clone was GVHD-specific. Also, V17 followed a similar trend to that seen in V15.
Lastly, we looked at Vs 9 and 20 from the group of Vs commonly associated with GVHD-free
patients to see if there was a correlation with GVT response, as well as at V6 since there was also an
increase in qRT-PCR expression for this V family (Figures 23, 24c,d). With regards to V9, an
oligoclonal population emerged over at polyclonal background at R4. This clone wa not likely involved
in a GVT response, since it was at the time of relapse (R4) and prior to DLI treatments (prior to and after
R5), at which a GVT-specific clone should have disappeared by R4 or appeared after R5. V20
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demonstrated polyclonality from R3-R6, demonstrating that it was not involved in an antigen-driven
response. In V6, there was a skewed repertoire from R3-R5 that became more oligoclonal at R6,
suggesting a clonally-driven response involved in either GVHD or GVT effects.
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Figure 23:

Figure 23. Expression of V families in Patient 10. D: donor sample at time of transplantation; R2:
recipient sample 3 months post-transplant; R3: time of GVHD onset at 6 months post-HSCT; R4: time
of relapse at 10 months post-HSCT; R5: 1-year post HSCT, one month after 1st DLI treatment; R6: 22
months post-HSCT, two months after 2nd DLI treatment, time of remission and re-onset of chronic skin
GVHD.
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Figure 24
24a)

Figure 24. Spectratyping analysis for Patient 10. a) Spectratyping of V families 4, 11, and 23 in
Patient 10. D: donor sample at time of transplantation; R2: recipient sample 3 months post-transplant;
R3: time of GVHD onset at 6 months post-HSCT; R4: time of relapse at 10 months post-HSCT; R5: 1year post HSCT, one month after 1st DLI treatment; R6: 22 months post-HSCT, two months after 2nd
DLI treatment, time of remission and re-onset of chronic skin GVHD.
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Figure 24b:

Figure 24b) Spectratyping analysis of V families 2, 4, 7, 8, 12, 15, and 17 in Patient 10. D: donor
sample at time of transplantation; R2: recipient sample 3 months post-transplant; R3: time of GVHD
onset at 6 months post-HSCT; R4: time of relapse at 10 months post-HSCT; R5: 1-year post HSCT, one
month after 1st DLI treatment; R6: 22 months post-HSCT, two months after 2nd DLI treatment, time of
remission and re-onset of chronic skin GVHD.
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Figure 24c:

Figure 24d:

Figures 24: c) Spectratyping of V families 9 and 20in Patient 10; d) Spectratyping of V6 in Patient
10. D: donor sample at time of transplantation; R2: recipient sample 3 months post-transplant; R3: time
of GVHD onset at 6 months post-HSCT; R4: time of relapse at 10 months post-HSCT; R5: 1-year post
HSCT, one month after 1st DLI treatment; R6: 22 months post-HSCT, two months after 2nd DLI
treatment, time of remission and re-onset of chronic skin GVHD.

79

Discussion

Our identification of specific T cell clonotypes commonly associated with GVHD or GVT supports
the dominant characterization of GVHD as a T-cell-mediated inflammatory disease and the role for Tcell-mediated alloreactivity in both GVHD and GVT responses.7,28,31 Current treatment of GVHD, both
prophylactic and established, consists of broad immunosuppression, which not only mediates GVHD,
but also increases the risk for opportunistic infection and incidence of relapse secondary to decreased
GVT responses. The ability to identify T cell clones involved not only in GVHD but also in GVT would
allow targeted depletion of GVHD-associated clones and augmentation of those involved in GVT
responses.
By isolating RNA rather than DNA from peripheral T cells, our results are more representative of
those TCR V that were transcribed to mRNA for protein translation. Since oligoclonal and monoclonal
CDR3 patterns are associated with strong immune responses, looking at mRNA expression by qRT-PCR
and spectratyping of the CDR3 region allowed us to identify T cell clonotypes involved in antigendriven responses.52 By identifying V families that met both of these criteria, we were able to make
temporal associations of T-cell-mediated responses at the time of GVHD, as well in association of GVT
effects in the absence of any clinically noted infections.
GVHD
Though we isolated RNA from un-separated T cells, several studies have noted the association of
skewed, oligoclonal T cell populations with CD8+ subsets and polyclonal populations with CD4+
subsets.67,68 In one such study characterizing T cell expansions in patients with myelodysplastic
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syndromes (MDS), Fozza et al. observed that increased frequencies of expanded variable subfamilies
in CD4+ and CD8+ T cells were mostly Gaussian, or skewed and oligoclonal, respectively, within the
CDR3 regions.67 In the general characterizations of GVHD and GVT as T-cell-mediated responses,
CD8+ CTLs damage cells bearing class I MHC, typically in the skin, gut, and liver in GVHD, and in
myeloid or lymphoid tissues in GVT.31,69 Our spectratyping results coincide with these observations, as
oligoclonality has been associated with the CD8+ subset.
Most studies characterize GVHD as a Th1- and Tc1-type cytokine mediated process, though this
characterization is not absolute. For example, though Th1- and Tc1-type cells are abundant sources of
IFN-γ, which primes macrophages and monocytes for pro-inflammatory cytokine secretion, IFN-γ has
also been shown to induce apoptosis in lymphocytes.70 Th1-type cytokines have been correlated with
amplifying the development of aGVHD, whereas Th2 cells have been shown to reduce aGVHD.10,41
Furthermore, though the alloreactive T-cell-mediated inflammatory response characterizes GVHD, this
pathophysiology is broadly accepted with regards to aGVHD, as cGVHD is still less well understood.3,17
Since cGVHD is represented as more of an antigen-specific cellular and humoral immune response,16
the role for CD4+ T cells is more plausible for chronic rather than acute GVHD. It is also thought that
antigenic spread and exposure may lead to the generation of autoreactive T cells, which have been
implicated in the pathogenesis of cGVHD.3,17,57 Even if we accept the Th1- and Tc1- cytokine profiles
as being restricted to aGVHD only, five out of eight GVHD patients had aGVHD. As such, the
argument for CD8+ CTL function is concrete for those five patients, yet entirely plausible for the three
patients whose GVHD was defined as chronic, as their clonality profiles were similar to those with
aGVHD. Furthermore, though CD8+ subsets are the major cytotoxic effectors in GVHD, CD4+ T cells
have been shown to have cytotoxic functions in a MHC class II restricted manner.34,71 Since our patients
who developed GVHD did not have class I or II mismatches (with the exceptions of Patients 13 and 14
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(Table 1)), we can reasonably suggest that GVHD-specific CTL function is peptide-dependent in the
context of mHAgs.
Furthermore, because the thymus and bone marrow environments are susceptible to damage by preconditioning treatments, regeneration of lymphoid-derived T cells is limited after HSCT.72 Though de
novo generation of T cells from progenitors occurs via thymopoiesis, peripheral expansions of residual
mature T cells are also a major contributing pathway in T cell reconstitution.62 After HSCT while
patients are lymphopenic, any remaining residual host T cells and the donor T cells transferred within
the graft undergo homeostatic peripheral expansion (HPE). These early HPEs are typically
characterized by oligoclonal and skewed repertoires, as peripheral expansions of mature lymphocytes
are driven by antigen stimulation and/or homeostatic cytokines.62 Under the premise that HPE augments
the environment for alloreactive T cell clones, it may be possible to identify GVHD-associated clonal
populations prior to clinical diagnosis, especially in instances in which GVHD onset is around the time
of tapering or ending of prophylactic immunosuppression, as in our Patients 5, 6, 8, 9, and 10. The
onset of GVHD for Patients 11, 13, and 14 occurred while they were still on immunosuppression,
showing the ability of HPE to augment expansion of alloreactive T cell clones, even if to a lesser degree,
as immunosuppression does not abrogate the allorecognition itself.
It has been shown that HPE of CD8+ T cells is more efficient than HPE of CD4+ cells, resulting in
reduced CD4+ T cell counts and inverted CD4/CD8 ratios for months to years following HSCT in hosts
with limited thymic function.62 This supports the likelihood of GVHD-associated clones representing
CD8+ T cells, as CD4+ T cell number and function highly depends upon thymic-dependent T cell
regeneration, which only occurs in a small fraction of adults who undergo HSCT.72 Furthermore, there
has been an association of Th2 cytokine subsets and Tregs with lower incidence/severity of aGVHD.37,41
With delayed restoration of the CD4+ subset after HSCT, the ability to downregulate T cell proliferation
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is greatly hindered,36 thus allowing the continued expansion of alloreactive T cell populations involved
in the pathogenesis of GVHD.
Diverse T cell repertoires may not be restored until thymopoiesis is restored, and although the
thymus is involuted after puberty, it is still capable of generating new T cells, albeit at a much slower
rate.73 In adults, each successive decade reduces the incidence of re-establishment of thymopoiesis, thus
reducing the level of naïve cells produced and exported into the peripheral blood.74 Over the age of 45
(as in all of our patients at the time of HSCT except for one at age 44), the frequency of significant
renewal of thymopoiesis is severely reduced and normal levels of naïve CD4+ T cells may not be
reached until after 2 years.74 In many older adults, this recovery of a normal level may take 3-5 years,
and in some, may remain below normal levels for decades [reviewed in Williams].62 Because of delayed
thymopoiesis, we are not surprised to find that some patients who were used as controls for their low
qRT-PCR expression of certain TCR V families demonstrated aberrant T cell repertoires, as a normal
Gaussian distribution may take years to be re-established. Furthermore, as Patient 8 was under
immunosuppression throughout his course of treatment (R2-R4), it was not surprising to see
oligoclonality in many V families that had low expression, as the reconstitution of his T cell repertoire
was continually suppressed. Similarly, early increases in expression of a V family showing an aberrant
or skewed repertoire (at a non-disease time) followed by decreased expression and polyclonality may
merely represent the typical T cell reconstitution seen in patients after HSCT—HPE driven by
homeostatic cytokines during a time of insufficient thymopoiesis before restoration of diverse naïve
CD4+ T cells (which are characterized by polyclonal Gaussian spectratyping of the CDR3 region).62
Without any other clinically noted infections or complications at the same times as those of our
GVHD samples, we can reasonably propose that the clonotypes we identified may be the alloreactive
agents of GVHD within these patients. Our results (Vs 4, 11 and 23 in the GVHD group and Vs 2, 3,
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7, 8, 12, 15, 17 in the ―shared‖ GVHD/GVT group) are consistent with previous studies that have shown
that oligoclonal expansions of V families is common and often correlates with GVHD.53 In addition to
identifying T cell clones in the circulation of patients with GVHD, we were also able to identify some of
these V families at the site of GVHD. Other studies have shown that overall T cell repertoires in skin
lesions involved in GVHD differed from that in peripheral blood.57,75,76 We, however, were able to
identify some V families that were increased in the peripheral blood in an antigen-driven manner
(oligoclonality) that were also detectable at the site of skin and gut GVHD. From those V families
which we identified as being commonly associated with patients with GVHD (V4 –Patients 5, 6, 8, 10;
V11 – Patients 5, 8, 9, 10, 13; V23 – Patients 5, 9, 10, 11, 13), we were able to identify all Vs at the
site of GVHD in at least one patient: V4 –Patients 5, 6, 8; V11 – Patients 5, 8; V23 – Patient 5.
Aside from our GVHD-specific group of V families, some of the V families whose expression was
increased and also demonstrated oligoclonality in the peripheral blood in patients both with and without
GVHD (Vs 2, 3, 7, 8, 12, 15, 17) were detected at the site of GVHD: V2 – Patients 6, 11; Vs 3, 15,
17 – Patient 11.
Additionally, Liu et al. observed that GVHD-specific clones may be difficult to detect in peripheral
blood as the degree of expansion away from the site of disease is variable.53 We noticed this for a few
V families that were detected at the site of GVHD, though their expression was not increased in the
peripheral blood: V2 – Patients 5, 8; V9 – Patient 8; V23 – Patient 5. For Patient 5, the expression
of V2 was almost 9-fold lower than that of Donor 5, suggesting that this V family may in fact be
detected at the site of GVHD, but not by its level of expression in the blood. For Patient 8, both Vs 2
and 9 were roughly 2-fold lower than that of the donor, again suggesting that some GVHD-associated
clones may be detected at the site of disease but not in the peripheral blood. For all other Vs detected
84

at the site of GVHD, their respective expressions in the blood were at least 2-fold higher in the GVHD
samples than in the donor samples. On the other hand, V23 had less than 0.5-fold increased expression
over Donor 5, suggesting that it may be difficult to establish a baseline fold-increase that can be used as
a predictor of GVHD-specific clonotypes. We did not note a difference in the ability to detect clones
with regards to chronic or acute manifestation of GVHD, as we were able to identify at least half of the
V families that were oligoclonally increased in the periphery at the site of GVHD in patients with both
chronic (Patients 8, 11) and acute (Patients 5, 6) GVHD. There was also no strong difference in those
Vs that were detected in skin (Patients 8, 11) or gut (Patients 5, 6), as V2 was found in all patients and
Vs 4 and 11 were detected in both gut and skin GVHD. Furthermore, we were able to compare our
results with other groups that identified V families at the site of GVHD: C. Liu et al. detected Vs 2,
6, 17, and 23;53 Hirokawa, et al. identified V6;76 X. Liu et al. identified V2,77 and Beck et al.
identified Vs 3 and 17,57 all in skin GVHD.
In addition to V families detected at the site of GVHD, certain V families have been detected in
the skin of healthy adults, such as Vs 2, 3, 6, and 23,64,78 each of which we identified at the site of
GVHD (V2 – Patients 5, 6, 8, 11; Vs 3, 6, 23 – Patient 11). For V2, expression in the peripheral
blood was lower than that of the donors in Patients 5 and 8, but higher than the donors for Patients 6 and
11. We also detected V2 in our control sample (folliculitis), though there was a lack of both increased
expression and oligoclonality in the blood. If future studies detect V2 at the site of disease without an
increased expression or oligoclonality in the peripheral blood, then it may follow with observations
made by Menssen et al. that V2 commonly resides in the skin.64 Furthermore, V6 was detected at the
site of GVHD in Patient 11. Though there was a roughly 2-fold increase in expression of V6 relative
to Donor 11, the clonality was more suggestive of HPE than an antigen-driven response. For Patient 11,
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the two possibilities are that V6 may commonly reside in the skin or is detectable at the site of GVHD
without increased expression or oligoclonality in the blood. With future studies involving more patients,
we will be able to see if there is an association of Vs 2 and 6 at the site of GVHD with either high or
low expression in the blood. Using more control samples will also help to identify V families that
commonly reside in the skin or gut. If skin-resident V families are involved in the pathogenesis of
GVHD, then it suggests that conditioning regimen damage to host tissues causes activation of such T
cells at the site of GVHD, whereas those V families not common in the skin of healthy individuals are
recruited to the site of disease.
Though we isolated RNA from our peripheral blood samples, we isolated DNA from the GVHDbiopsy samples. Using DNA, those TCR V families identified at the site of GVHD were representative
of one copy per rearranged TCR per cell.57 We expected to detect V families at the site of GVHD that
were also detected in the peripheral blood. Exceptions to this were seen in instances in which V
families were detected at the site of GVHD without a corresponding increased expression in the blood,
with either polyclonal (V2 – Patient 5) or oligoclonal (V9 – Patient 8) repertoires in the blood. We
plan to use high throughput sequencing in order to determine whether higher copies of certain VDJ
recombination for a given TCR V may predict GVHD or GVT at a molecular level.
Furthermore, other studies have noted CD8+ T cell infiltrates at the site of GVHD,20 and the absence
of CD8+ infiltrates in normal, healthy skin.78 Future spectratyping analysis of the T cell clones detected
at the site of disease will help us determine which T cells are active in the disease (oligoclonal) and
which are bystanders common to the disease tissue (polyclonal).
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GVT
Studies have shown a correlation with aGVHD and improved disease-free survival, and that patients
with cGVHD from matched sibling donors correlate with fewer relapses (though also increased
TRM).17,25,79 For these reasons, the question then remains as to whether the mechanisms and effectors
for GVHD and GVT are fundamentally different.53 This question is especially prominent when we
consider the augmentation of antigen-driven T cell responses early-on after transplantation when
homeostatic cytokines promote T cell expansion, which primes the environment for both GVHD and
GVT responses. It has also been shown that GVT effects can occur in the absence of GVHD, which
implies that certain mHAgs that are expressed by malignancies are not expressed on the nonhematopoietic-restricted tissues that are targeted in GVHD.9,15 However, with clinical observations that
associate GVT with GVHD, there may be an overlap of mHAg expression, though those mHAgs that
are only expressed on hematopoietic cells have become the target of interest for their potential roles in
augmenting GVT effects.43 Though our patients are heterogeneous with regards to disease, the
potential to identify T cells involved in GVT effects is plausible in the context of mHAgs whose
expression is limited to the hematopoietic system.
Within the group of GVHD-free patients (3, 4, 7, 12), Vs 9, 16, and 20 demonstrated both
increased expression and oligoclonality, suggesting a GVT-role for these T cells. Patient 3 also
demonstrated increased expression and clonality in Vs 5 and 24, which implies that GVT-specific T
cells recognize mHAgs that are unique to that individual. Of the Vs we identified in either our
GVHD-free or GVHD patients, a few other studies have associated some of these V families in the
peripheral blood with various diseases: Tan et al. noted oligoclonal expansions of Vs 3 and 15 in
patients with diffuse large B-cell lymphoma (DLBL)80 and Tanaka-Harada et al. observed biased usage
of Vs 9 and 15 in acute myeloid leukemia (AML), Vs 4 and 12 in myelodysplastic syndrome (MDS),
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and Vs 5 and 20 in patients with AML and MDS (as well as in healthy donors),81 suggesting the
ability to identify V families that recognize mHAg in a hematopoietic-restricted manner.
GVT responses are generally thought to involve T-cell-mediated cytotoxicity, with CD8+ subsets
being the predominant CTLs.82 However, CD4+ subsets are also recognized as having cytolytic
effector functions,28, 34-36 suggesting their potential role in cytotoxic-mediated GVT responses as well.
With the exception of Patient 10, all of our patients were relapse-free, which broadens the possibility of
GVT-associated T cells being identified in more than just those four patients who did not develop
GVHD. Furthermore, three of our patients had HLA-DQB1 mismatches (Patients 4, 7, 13). Since class
II genes are restricted to hematopoietic antigen presenting cells, these mismatches may promote a GVT
effect in an mHAg-independent or mHAg:MHC-dependent manner.9,25,44
Lastly, Patient 10 allowed us to look for GVT-associated clones that disappear at the time of relapse.
V11 was the only TCR family that met this criterion, suggesting a role for V11 in GVT, as opposed
to GVHD, as GVHD was not clinically resolved at the time of relapse. We also expected to see new
oligoclonal populations emerge at R6, which was defined as post-DLI remission and GVHD. New
clones did emerge in Vs 2, 7, 11, and 23, suggesting potential roles for these Vs in either GVHD or
GVT responses. Patient 10’s remission after DLI treatments demonstrates the GVT effect in
eradicating her disease.32 Since GVHD is also common after DLI treatments, 16,27,65,66 the specificity of
these clones will help distinguish which clones may be involved in which process.
Clinical Correlations
Overall, when we look at the patients in this study and consider major risk factors (HLA-mismatch,
female donor to male recipient, PBSC vs. BM) that are associated with development of GVHD, we
were able to make a few observations that will be better validated with a larger patient cohort in the
future. With regards to HLA-matching, a mismatch at any of the HLA- A, -B, -C, and –DRB1 alleles
88

has been associated with worse overall survival (OS).83 All patients were 8/8 matches for these four
HLA-alleles, with the exception of Patient 14, who had an HLA-B mismatch (Table 1). Patient 14
developed late-onset acute GVHD of both skin and the GI system, and also died six months after
HSCT, showing a direct correlation with the increased risk factors associated with the HLA-B
mismatch. Also, Patient 14’s GVHD was likely due to HLA-disparity, since the prevalence of
aGVHD is upwards of 60-80% in recipients of grafts with one HLA allele mismatch.4 Mismatches of
the DQB1 allele have not been shown to have an impact on OS or increased incidence of GVHD.83
Two of our three patients with an HLA-DQB1 mismatch were GVHD-free and are still alive over two
years post-HSCT, and the one who developed aGVHD is still alive over one year post-HSCT.
Many studies have noted an increased risk of GVHD when a male recipient receives a graft from a
female donor, due to H-Y antigens.15,28,42 Two patients, 9 and 14, were male recipients of female
grafts, and both developed aGVHD. Antibodies specific for H-Y mHAgs have been associated with
cGVHD,84 whereas each of these two patients developed aGVHD and also demonstrated increased
expression and oligoclonality in their T cell repertoires, supporting the role of alloreactive T cells in
their GVHD responses.
Donor grafts from PBSC have been associated with a greater incidence of GVHD, though grafts
from BM have been associated with increased risk of relapse.85 All of our patients received PBSC,
with the exception of Patients 10 and 13. Patient 10 was the only patient in our study to relapse, which
resolved after DLI treatments. Interestingly, after Patient 10 went into remission, she developed
GVHD again, showing the role of donor lymphocytes in promoting GVT effects as well as augmenting
GVHD. A study by the CIBMTR showed that CD34+ cell doses from PBSC grafts greater than 6 x
106/kg were associated with decreased risk of relapse.86 The average CD34+ cell dose in our GVHDfree group was 7.03 x 106/kg, whereas in our GVHD group, it was 4.54 x 106/kg (Table 3). All of the
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patients in the GVHD-free group had cell doses greater than 6 x 106/kg, whereas only two patients in
the GVHD-group did (Patients 8 and 9). This suggests that higher CD34+ cell doses help facilitate
better reconstitution of the immune system, as pointed out in Ringdén et al. 2009,69 and thus increase
GVT effects. Furthermore, two of our patients received BM grafts, Patients 10 and 13, with cell doses
of 3.43 and 1.9 x 106/kg, respectively (Table 3). Bone marrow grafts are associated with greater
incidence of relapse, as opposed to PBSC grafts, which was evidenced by Patient 10’s relapse.85
Furthermore, the higher amount of CD3+ T cells in PBSC grafts is also associated with increased
incidence of GVHD.7 Interestingly, Patient 11 had the highest CD3+ T cell dose (11.35 x 108/kg) and
developed GVHD faster than all other patients, though only by a few days (Tables 2 and 3). However,
Patient 13 had the lowest CD3+ dose (4.3 x 107/kg, from a BM graft) and also developed GVHD (Table
3). Overall, there was no significant correlation of cell dose with increased incidence of GVHD in this
cohort of patients. Furthermore, early donor T cell chimerisms are also associated with increased risk
of GVHD, which was observed in our patients (Table 2).
Conclusion
In summary, we were able to identify three groups of TCR V families that were associated with
either GVHD or GVT effects, or were commonly associated with both GVHD and GVT. Our findings
suggest that GVHD-associated T cell clones can be identified at the time of GVHD and used for
targeted therapy of GVHD by means of TCR V-specific antibodies or small molecules that can target
the associated T cell clones. For those V families that were common between GVHD and GVT
groups, we need a larger number of patients to determine whether these V families may be associated
with GVHD and/or GVT. For those patients with GVHD, if the mHAg:MHC complexes are expressed
on cells both in the hematopoietic system and at the site of GVHD, it may well be that the same T cell
populations are involved in both GVHD and GVT responses. Future molecular analysis may also
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reveal that there are CDR3 sequences common across TCR V families, which would suggest that
CTLs from various V families may be able to recognize the same antigen with different avidities.30
Though the majority of our patients do not have any HLA-mismatches, analysis of T cell subsets
(CD8+ versus CD4+) may help us correlate the HLA-DQB1 mismatches with CD4+ recognition, as well
as better understand the cytokine profiles of both acute and chronic GVHD. Regardless of CD8+ or
CD4+ subset, we observed clonal expansions of TCR V families that are indicative of antigen-driven
responses. For oligoclonal populations that emerge before the time of clinical diagnosis of GVHD, we
may be able to detect GVHD-associated clones before clinical manifestation of the disease,
demonstrating a potential role for T cell clonality in prognostics. On the other hand, clonal populations
that emerge prior to clinical diagnosis of GVHD may be involved in GVT responses. We need to
determine the fine specificity of GVHD- and GVT-associated TCR Vs in order to develop targeted
therapies. In this regard, high-throughput sequencing will allow us to identify the specificity of these
clonotypes based on their CDR3 sequences.
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